prednisone has been researched along with Anti-MuSK Myasthenia Gravis in 394 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Current myasthenia gravis guidelines recommend the use of azathioprine as first-line steroid sparing agent." | 9.41 | Methotrexate in generalized myasthenia gravis: a systematic review. ( Adiao, KJB; Prado, MB, 2023) |
| "The Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone (MGTX) showed that thymectomy combined with prednisone was superior to prednisone alone in improving clinical status as measured by the Quantitative Myasthenia Gravis (QMG) score in patients with generalised non-thymomatous myasthenia gravis at 3 years." | 9.30 | Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. ( Aban, IB; Amato, AA; Antonini, G; Barboi, AC; Barohn, RJ; Benatar, M; Beydoun, SR; Buckley, C; Cea, JG; Chalk, CH; Ciafaloni, E; Conwit, R; Cutter, GR; Dias-Tosta, E; Evoli, A; Heckmann, JM; Jackson, CE; Jaretzki, A; Kaminski, HJ; Katirji, B; King, JO; Kissel, JT; Kostera-Pruszczyk, A; Kuo, HC; Lecky, BRF; Marx, A; Massey, JM; Mazia, C; Minisman, G; Mozaffar, T; Newsom-Davis, J; Nix, W; Oger, J; Pascuzzi, RM; Pulley, MT; Rivner, MH; Shaibani, AI; Silvestri, NJ; Sonett, JR; Ströbel, P; Tandan, R; Verschuuren, JJGM; Vincent, A; Waddington-Cruz, M; Werneck, LC; Witoonpanich, R; Wolfe, GI; Yoshikawa, H, 2019) |
| "To determine the steroid-sparing effect of methotrexate (MTX) in patients with symptomatic generalized myasthenia gravis (MG)." | 9.22 | A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. ( Barohn, RJ; Becker, M; Benatar, M; Bril, V; Burns, TM; David, W; Dimachkie, MM; Elsheikh, BH; Goyal, N; He, J; Herbelin, L; Howard, JF; Jackson, C; Kissel, JT; Mozaffar, T; Nations, S; Pasnoor, M; Pazcuzzi, R; Pulley, M; Rosenfeld, J; Saperstein, D; Shaibani, JA; Simpson, E; Statland, JM; Swenson, A; Wang, AK; Wicklund, M, 2016) |
| "To test the hypothesis that mycophenolate mofetil (MMF) with prednisone provides better control of myasthenic weakness than prednisone alone in the initial management of generalized myasthenia gravis (MG)." | 9.13 | A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. ( , 2008) |
| "Seventy-nine patients with cyclosporine- and prednisone-dependent myasthenia gravis (MG) after thymectomy received tacrolimus for a mean of 2." | 9.11 | Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. ( Armengol, M; Azem, J; Buera, M; Cervera, C; Fort, JM; López-Cano, M; Ponseti, JM; Vilallonga, R, 2005) |
| "To explore the clinical effect of Tripterygiitotorum (T II) combined with prednisone in treating patients with myasthenia gravis (MG) and the changes of immune function after treatment." | 9.10 | [Clinical effect of Tripterygiitotorum combined with prednisone and its effect on serum IL-6 level in treating patients with myasthenia gravis]. ( Li, ZX; Tan, H; Xiong, XJ, 2002) |
| "Ten patients with myasthenia gravis were randomized to azathioprine or prednisone as the initial immunomodulating drug and followed for over one year." | 9.08 | Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. ( Albers, JW; Bromberg, MB; Feldman, EL; Forshew, DA; Wald, JJ, 1997) |
| "From January 1983 to October 1990, 41 patients with generalised myasthenia gravis were randomly given either prednisone or azathioprine." | 9.07 | A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group. ( , 1993) |
| "We randomly assigned 39 patients with steroid-dependent generalized myasthenia gravis to treatment with cyclosporine (5 mg/kg per body weight in divided doses) or placebo." | 9.07 | A clinical therapeutic trial of cyclosporine in myasthenia gravis. ( Hall, K; Phillips, JT; Rollins, JA; Tindall, RS; Wells, L, 1993) |
| "This systematic review will measure the QMG and the dose of prednisone required, the myasthenia gravis activities of daily living scale scores (MG-ADL), treatment-associated complications, incidence of myasthenic crisis and other aspects to comprehensively assess the clinical benefits of thymectomy plus prednisone for MG patients without thymoma." | 9.05 | Effectiveness and safety of thymectomy plus prednisone compares with prednisone monotherapy for the treatment of non-thymomatous Myasthenia Gravis: Protocol for a systematic review. ( Hong, X; Liu, D; Sun, H; Wang, W; Yang, B; Yang, H; Zheng, Y, 2020) |
| "This study was performed to evaluate the efficacy and long-term safety of tacrolimus for young children with myasthenia gravis (MG)." | 8.31 | Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis. ( Li, W; Zhang, L; Zhang, M; Zhang, Y; Zhou, S, 2023) |
| "We observed that oral administration of 3 mg tacrolimus daily for 1 year can significantly improve the clinical symptoms of patients with refractory myasthenia gravis, which is characterized by a significant reduction in clinical scores, such as QMG, MMT, ADL, MGQOL-15, and a reduction daily oral prednisolone (PSL) dose (P < 0." | 8.12 | Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis. ( Chen, L; Wu, H; Wu, Y; Xue, Q; Yan, Y; Zhao, C; Zhou, X; Zhu, Y, 2022) |
| "To investigate the clinical efficacy of Fufang Huangqi decoction in combination with pyridostigmine bromide tablets, prednisone, and tacrolimus in the treatment of type I and II myasthenia gravis (MG) through changes in the clinical symptom scores of 100 patients with type I and II MG." | 8.12 | Effect of treatment with Fufang Huangqi decoction on dose reductions and discontinuation of pyridostigmine bromide tablets, prednisone, and tacrolimus in patients with type I or II myasthenia gravis. ( Caifeng, S; Haiou, P; Jingsheng, Z; Wenjun, Q; Xueshi, H; Yi, L; Zhanyou, W, 2022) |
| "Based on the results of this small retrospective study, it seems initial treatment for ocular myasthenia gravis with a mean maximum daily prednisone dose of 10 mg is similarly effective compared with mean maximum daily dose of 29 mg for control at 1 month." | 8.02 | Effect of Initial Prednisone Dosing on Ocular Myasthenia Gravis Control. ( Carey, AR; Henderson, AD; Shah, YS, 2021) |
| "A retrospective observational cohort study was conducted to evaluate the efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV myasthenia gravis (MG) patients." | 7.88 | Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis. ( Cao, M; Fang, XJ; Jiang, QL; Liang, Y; Liu, XM; She, SF; Wang, SS; Zhao, LN, 2018) |
| "To estimate the satisfactory response rate (SR%) with achieving maintenance, low-dose prednisone in acetylcholine receptor antibody-positive generalized myasthenia gravis." | 7.88 | Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis. ( Abuzinadah, AR; Barohn, RJ; Dimachkie, MM; Glenn, M; Herbelin, L; Jabari, D; Jawdat, O; McVey, AL; Pasnoor, M, 2018) |
| "Children with myasthenia gravis who had not achieved satisfactory improvement or who experienced severe side effects after prednisone therapy were recruited between January 2015 and December 2016 at Tongji Hospital." | 7.85 | Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone. ( Bu, B; Cao, Y; Gui, M; Ji, S; Li, Y; Lin, J; Liu, C, 2017) |
| " We hypothesized that a long-term low-dose prednisone regimen for ocular myasthenia gravis (OMG) would have a low rate of major side effects." | 7.78 | Safety of prednisone for ocular myasthenia gravis. ( Bruce, BB; Kupersmith, MJ, 2012) |
| " We report a unique case of a 64-year-old woman who had been on prednisone monotherapy for the treatment of myasthenia gravis and subsequently developed cryptococcal cellulitis." | 7.72 | Cryptococcal cellulitis in a patient on prednisone monotherapy for myasthenia gravis. ( Beaty, S; Colome-Grimmer, MI; Dotson, AD; Lafleur, L; LaForte, RA, 2004) |
| "Prednisone therapy and intravenous gamma globulin may be helpful in patients with generalized myasthenia gravis complicating HIV infection." | 7.70 | Seronegative myasthenia gravis and human immunodeficiency virus infection: response to intravenous gamma globulin and prednisone. ( Strong, J; Zochodne, DW, 1998) |
| "The influence of age at onset, sex, duration of disease and severity degree on the response to therapy have been evaluated in 30 patients with myasthenia gravis treated with prednisone." | 7.68 | [Predictive factors of the response to treatment of myasthenia gravis with prednisone]. ( Illa, I; Pradas, J, 1990) |
| "Twenty-four patients with myasthenia gravis were treated with azathioprine." | 7.67 | Azathioprine in the treatment of myasthenia gravis. ( Cornblath, DR; Lisak, RP; Parry, GJ; Schatz, NJ; Witte, AS, 1984) |
| "In patients with myasthenia gravis who received single doses of prednisone orally (40 to 100 mg), we found acute inhibition of neuromuscular function as manifest by increased decremental responses to repetitive nerve stimulation, reduced twitch tension, and lowered maximum voluntary contraction strength." | 7.67 | Prednisone-induced worsening of neuromuscular function in myasthenia gravis. ( Miller, RG; Milner-Brown, HS; Mirka, A, 1986) |
| " They started approximately 4 months after the patient had begun a regimen of prednisone and cyclophosphamide for myasthenia gravis." | 7.67 | Multiple dermatofibromas in a patient with myasthenia gravis treated with prednisone and cyclophosphamide. ( Bargman, HB; Fefferman, I, 1986) |
| "A 40-year-old woman with clinical and laboratory features of myasthenia gravis, hyperthyroidism, and polymyositis responded to treatment with prednisone alone." | 7.66 | Prednisone use in concurrent autoimmune diseases. ( Harati, Y; Patten, BM, 1979) |
| "To determine the effects of alternate-day prednisone therapy on respiratory function in myasthenia gravis, eight patients were evaluated during "days on" and "days off" prednisone." | 7.65 | Effects of alternate-day prednisone therapy on respiratory function in myasthenia gravis. ( Brahim, SA; Newball, HH, 1976) |
| "Myasthenia gravis is an autoimmune neuromuscular disorder caused by antibodies directed against proteins present at the post-synaptic surface of neuromuscular junction resulting in weakness." | 6.79 | Serum metabolomic response of myasthenia gravis patients to chronic prednisone treatment. ( Cheema, A; Kaminski, HJ; Kusner, LL; Sengupta, M, 2014) |
| "Prednisone was given at the lowest dose to manage MG symptoms and adjusted as required according to protocol." | 6.76 | A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. ( Badri, M; Bateman, K; Heckmann, JM; Rawoot, A; Renison, R, 2011) |
| "Thymectomy is a standard treatment of myasthenia gravis (MG)." | 6.73 | Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study. ( Armengol, M; Azem, J; Buera, M; Fort, JM; Gamez, J; López-Cano, M; Ponseti, JM; Vilallonga, R, 2007) |
| "Thymectomy is a standard treatment of myasthenia gravis (MG)." | 6.72 | Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis. ( Armengol, M; Azem, J; Fort, JM; Gamez, J; López-Cano, M; Ponseti, JM; Vilallonga, R, 2006) |
| "This study evaluated the clinical efficacy of leflunomide combined with low-dose prednisone (0." | 5.91 | Clinical evaluation of efficacy of leflunomide combined with low-dose prednisone for treatment of myasthenia gravis. ( Chen, J; Huang, X; Liu, W; Lu, Y; Ou, C; Qiu, L; Ran, H; Yang, W, 2023) |
| "High-dose prednisone use, lasting several months or longer, is the primary initial therapy for myasthenia gravis (MG)." | 5.69 | Serum metabolomics of treatment response in myasthenia gravis. ( Aban, I; Cheema, M; Kaminski, HJ; Kusner, LL; Li, Y; Sikorski, P; Wolfe, GI, 2023) |
| "Azathioprine (AZA) has been shown to be effective for MG with a significant steroid-sparing activity, although burdened by side effects." | 5.62 | Methotrexate as a Steroid-Sparing Agent in Myasthenia Gravis: A Preliminary Retrospective Study. ( Bonanno, C; Brizzi, T; Lupica, A; Musumeci, O; Nicocia, G; Pugliese, A; Rodolico, C; Toscano, A; Trimarchi, G, 2021) |
| "Leflunomide is an effective drug used in the treatment of rheumatoid arthritis." | 5.43 | Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study. ( Chen, P; Deng, J; Feng, H; Liu, W; Luo, Y; Ou, C; Qiu, L, 2016) |
| "Current myasthenia gravis guidelines recommend the use of azathioprine as first-line steroid sparing agent." | 5.41 | Methotrexate in generalized myasthenia gravis: a systematic review. ( Adiao, KJB; Prado, MB, 2023) |
| "To examine whether sustained minimal manifestation status (MMS) with complete withdrawal of prednisone is better achieved in thymectomized patients with myasthenia gravis (MG)." | 5.34 | Minimal manifestation status and prednisone withdrawal in the MGTX trial. ( Aban, IB; Amato, AA; Antonini, G; Barboi, AC; Barohn, RJ; Benatar, M; Beydoun, SR; Buckley, C; Cea, G; Chalk, CH; Ciafaloni, E; Conwit, R; Cutter, GR; Dias-Tosta, E; Evoli, A; Heckmann, JM; Jackson, CE; Kaminski, HJ; Katirji, B; King, JO; Kissel, JT; Kostera-Pruszczyk, A; Kuo, HC; Lecky, BRF; Lee, I; Massey, JM; McPherson, T; Minisman, G; Mozaffar, T; Nix, W; Oger, J; Pascuzzi, RM; Pulley, MT; Rivner, MH; Shaibani, AI; Sonett, JR; Ströbel, P; Sussman, J; Tandan, R; Verschuuren, JJG; Vincent, A; Waddington-Cruz, M; Werneck, LC; Witoonpanich, R; Wolfe, GI; Yoshikawa, H, 2020) |
| "Fifty percent of ocular myasthenia gravis (OMG) patients will progress to generalized myasthenia, 90% within 3 years from the onset of ocular symptoms." | 5.32 | The effect of prednisone on the progression from ocular to generalized myasthenia gravis. ( Goldstein, JM; Knorr, AM; Lesser, RL; Monsul, NT; Patwa, HS, 2004) |
| "The Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone (MGTX) showed that thymectomy combined with prednisone was superior to prednisone alone in improving clinical status as measured by the Quantitative Myasthenia Gravis (QMG) score in patients with generalised non-thymomatous myasthenia gravis at 3 years." | 5.30 | Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. ( Aban, IB; Amato, AA; Antonini, G; Barboi, AC; Barohn, RJ; Benatar, M; Beydoun, SR; Buckley, C; Cea, JG; Chalk, CH; Ciafaloni, E; Conwit, R; Cutter, GR; Dias-Tosta, E; Evoli, A; Heckmann, JM; Jackson, CE; Jaretzki, A; Kaminski, HJ; Katirji, B; King, JO; Kissel, JT; Kostera-Pruszczyk, A; Kuo, HC; Lecky, BRF; Marx, A; Massey, JM; Mazia, C; Minisman, G; Mozaffar, T; Newsom-Davis, J; Nix, W; Oger, J; Pascuzzi, RM; Pulley, MT; Rivner, MH; Shaibani, AI; Silvestri, NJ; Sonett, JR; Ströbel, P; Tandan, R; Verschuuren, JJGM; Vincent, A; Waddington-Cruz, M; Werneck, LC; Witoonpanich, R; Wolfe, GI; Yoshikawa, H, 2019) |
| " Inclusion criteria will include the following: a Myasthenia Gravis Foundation of America (MGFA) clinical classification between I and IV while on optimal anticholinesterase therapy with or without oral prednisone or immunosuppressive therapy, an MG history of longer than 3 years, being 18 to 60 years of age, and positive testing for serum acetylcholine receptor antibodies (AchR-Ab)." | 5.27 | Optimal timing of thymectomy in nonthymomatous myasthenia gravis patients in China: A prospective study. ( Jiang, Q; Liu, F; Pan, J; Wen, Y, 2018) |
| " Long-term administration of steroids, with the attendant complication of growth retardation, is avoided." | 5.26 | Effective treatment of infantile myasthenia gravis by combined prednisone and thymectomy. ( Lewis, JE; McGarry, JD; Sarnat, HB, 1977) |
| "To determine the steroid-sparing effect of methotrexate (MTX) in patients with symptomatic generalized myasthenia gravis (MG)." | 5.22 | A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. ( Barohn, RJ; Becker, M; Benatar, M; Bril, V; Burns, TM; David, W; Dimachkie, MM; Elsheikh, BH; Goyal, N; He, J; Herbelin, L; Howard, JF; Jackson, C; Kissel, JT; Mozaffar, T; Nations, S; Pasnoor, M; Pazcuzzi, R; Pulley, M; Rosenfeld, J; Saperstein, D; Shaibani, JA; Simpson, E; Statland, JM; Swenson, A; Wang, AK; Wicklund, M, 2016) |
| " Patients who underwent thymectomy had a lower time-weighted average Quantitative Myasthenia Gravis score over a 3-year period than those who received prednisone alone (6." | 5.22 | Randomized Trial of Thymectomy in Myasthenia Gravis. ( Aban, IB; Amato, AA; Antonini, G; Barboi, AC; Barohn, RJ; Benatar, M; Beydoun, SR; Buckley, C; Cea, JG; Chalk, CH; Ciafaloni, E; Conwit, R; Cutter, GR; Dias-Tosta, E; Evoli, A; Garcia Ramos, GS; Heckmann, JM; Jackson, CE; Jaretzki, A; Kaminski, HJ; Katirji, B; King, JO; Kissel, JT; Kostera-Pruszczyk, A; Kuo, HC; Lecky, BR; Marx, A; Massey, JM; Mazia, C; Minisman, G; Mozaffar, T; Newsom-Davis, J; Nix, W; Odenkirchen, J; Oger, J; Pascuzzi, RM; Pulley, MT; Rivner, MH; Shaibani, AI; Sonett, JR; Ströbel, P; Tandan, R; Verschuuren, JJ; Vincent, A; Waddington-Cruz, M; Werneck, LC; Witoonpanich, R; Wolfe, GI; Yoshikawa, H, 2016) |
| "Initiation of mycophenolate mofetil (MMF) treatment was not superior to placebo in maintaining myasthenia gravis (MG) control during a 36-week schedule of prednisone tapering." | 5.13 | An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. ( De Baets, MH; Hart, IK; Mantegazza, R; Melms, A; Nicolle, MW; Richman, DP; Sanders, DB; Shukla, SS; Siddiqi, ZA; Solomons, N, 2008) |
| "To test the hypothesis that mycophenolate mofetil (MMF) with prednisone provides better control of myasthenic weakness than prednisone alone in the initial management of generalized myasthenia gravis (MG)." | 5.13 | A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. ( , 2008) |
| " Here, we report a case of a 75-year-old man with myasthenia gravis and metastatic melanoma who experienced complete and durable systemic regression after receiving pembrolizumab and single-lesion RT while on prednisone for myasthenia gravis prophylaxis and vedolizumab for immune-mediated colitis after previously experiencing mixed response on pembrolizumab monotherapy." | 5.12 | Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis. ( Clark, CA; Deshane, AS; Dobelbower, MC; Moradi, LA; Schneider, CS, 2021) |
| "MGTX Study is a multi-center, international, single-blinded, randomized trial to determine whether extended transsternal thymectomy (ETTX) for patients with myasthenia gravis receiving the prednisone protocol confers added benefits to the prednisone protocol alone." | 5.12 | [International project--MGTX study]. ( Yoshikawa, H, 2007) |
| "Seventy-nine patients with cyclosporine- and prednisone-dependent myasthenia gravis (MG) after thymectomy received tacrolimus for a mean of 2." | 5.11 | Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. ( Armengol, M; Azem, J; Buera, M; Cervera, C; Fort, JM; López-Cano, M; Ponseti, JM; Vilallonga, R, 2005) |
| "To explore the clinical effect of Tripterygiitotorum (T II) combined with prednisone in treating patients with myasthenia gravis (MG) and the changes of immune function after treatment." | 5.10 | [Clinical effect of Tripterygiitotorum combined with prednisone and its effect on serum IL-6 level in treating patients with myasthenia gravis]. ( Li, ZX; Tan, H; Xiong, XJ, 2002) |
| "Ten patients with myasthenia gravis were randomized to azathioprine or prednisone as the initial immunomodulating drug and followed for over one year." | 5.08 | Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. ( Albers, JW; Bromberg, MB; Feldman, EL; Forshew, DA; Wald, JJ, 1997) |
| "In this study we introduce a new combination treatment of plasma exchange (PE) and high daily doses of prednisone for severe forms of myasthenia gravis (MG)." | 5.08 | Plasmapheresis in severe forms of myasthenia gravis. ( Bernardi, G; Caramia, M; Casciani, CU; Galderisi, C; Gallucci, MT; Iani, C; Meloni, C; Morosetti, M; Palombo, G, 1998) |
| "From January 1983 to October 1990, 41 patients with generalised myasthenia gravis were randomly given either prednisone or azathioprine." | 5.07 | A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group. ( , 1993) |
| "We randomly assigned 39 patients with steroid-dependent generalized myasthenia gravis to treatment with cyclosporine (5 mg/kg per body weight in divided doses) or placebo." | 5.07 | A clinical therapeutic trial of cyclosporine in myasthenia gravis. ( Hall, K; Phillips, JT; Rollins, JA; Tindall, RS; Wells, L, 1993) |
| "9 subjects with myasthenia gravis, chronically treated with prednisone, underwent an open clinical trial with cyclosporine, an immunosuppressive and immunomodulator drug." | 5.06 | Results of an open trial of cyclosporine in a group of steroido-dependent myasthenic subjects. ( Antonini, G; Bove, R; Filippini, C; Millefiorini, M, 1990) |
| "This systematic review will measure the QMG and the dose of prednisone required, the myasthenia gravis activities of daily living scale scores (MG-ADL), treatment-associated complications, incidence of myasthenic crisis and other aspects to comprehensively assess the clinical benefits of thymectomy plus prednisone for MG patients without thymoma." | 5.05 | Effectiveness and safety of thymectomy plus prednisone compares with prednisone monotherapy for the treatment of non-thymomatous Myasthenia Gravis: Protocol for a systematic review. ( Hong, X; Liu, D; Sun, H; Wang, W; Yang, B; Yang, H; Zheng, Y, 2020) |
| "Thirteen patients with moderately severe myasthenia gravis participated in a double-blind study using either 100 mg of prednisone or an equivalen numbder of placebo tablets on alternate days." | 5.04 | Alternate-day prednisone: preliminary report of a double-blind controlled study. ( Daube, JR; Duane, DD; Howard, FM; Lambert, EH, 1976) |
| "This study was performed to evaluate the efficacy and long-term safety of tacrolimus for young children with myasthenia gravis (MG)." | 4.31 | Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis. ( Li, W; Zhang, L; Zhang, M; Zhang, Y; Zhou, S, 2023) |
| "We observed that oral administration of 3 mg tacrolimus daily for 1 year can significantly improve the clinical symptoms of patients with refractory myasthenia gravis, which is characterized by a significant reduction in clinical scores, such as QMG, MMT, ADL, MGQOL-15, and a reduction daily oral prednisolone (PSL) dose (P < 0." | 4.12 | Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis. ( Chen, L; Wu, H; Wu, Y; Xue, Q; Yan, Y; Zhao, C; Zhou, X; Zhu, Y, 2022) |
| "To investigate the clinical efficacy of Fufang Huangqi decoction in combination with pyridostigmine bromide tablets, prednisone, and tacrolimus in the treatment of type I and II myasthenia gravis (MG) through changes in the clinical symptom scores of 100 patients with type I and II MG." | 4.12 | Effect of treatment with Fufang Huangqi decoction on dose reductions and discontinuation of pyridostigmine bromide tablets, prednisone, and tacrolimus in patients with type I or II myasthenia gravis. ( Caifeng, S; Haiou, P; Jingsheng, Z; Wenjun, Q; Xueshi, H; Yi, L; Zhanyou, W, 2022) |
| "Based on the results of this small retrospective study, it seems initial treatment for ocular myasthenia gravis with a mean maximum daily prednisone dose of 10 mg is similarly effective compared with mean maximum daily dose of 29 mg for control at 1 month." | 4.02 | Effect of Initial Prednisone Dosing on Ocular Myasthenia Gravis Control. ( Carey, AR; Henderson, AD; Shah, YS, 2021) |
| " Long-term treatment response to IVIg was assessed by improvement in the Myasthenia Gravis Foundation of America (MGFA) clinical classification scale as primary end point, as well as the ability to reduce the time-weighted average required dose of prednisone as secondary end-point, in a follow-up period of 36 months." | 4.02 | Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis. ( Hellmann, MA; Lotan, I; Steiner, I; Wilf-Yarkoni, A, 2021) |
| "Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis Activities of Daily Living (MG-ADL) scales were compared using the data from the Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy (MGTX) study." | 3.96 | Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study. ( Aban, I; Cutter, G; Duda, PW; Farzaneh-Far, R; Kaminski, HJ; Lee, I; McPherson, T; Wolfe, GI, 2020) |
| "The thymectomy specimens from the "thymectomy trial in non-thymomatous myasthenia gravis patients receiving prednisone therapy" (MGTX) underwent rigid and comprehensive work-up, which permits analysis of the spatial distribution of histological and immunohistological features." | 3.88 | Histopathology of thymectomy specimens from the MGTX-trial: Entropy analysis as strategy to quantify spatial heterogeneity of lymphoid follicle and fat distribution. ( Aban, IB; Cutter, G; Deligianni, M; Grießmann, BW; Kaminski, HJ; Kayser, K; Marx, A; Scharff, C; Ströbel, P; Weis, CA; Wolfe, GI, 2018) |
| "A retrospective observational cohort study was conducted to evaluate the efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV myasthenia gravis (MG) patients." | 3.88 | Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis. ( Cao, M; Fang, XJ; Jiang, QL; Liang, Y; Liu, XM; She, SF; Wang, SS; Zhao, LN, 2018) |
| "To estimate the satisfactory response rate (SR%) with achieving maintenance, low-dose prednisone in acetylcholine receptor antibody-positive generalized myasthenia gravis." | 3.88 | Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis. ( Abuzinadah, AR; Barohn, RJ; Dimachkie, MM; Glenn, M; Herbelin, L; Jabari, D; Jawdat, O; McVey, AL; Pasnoor, M, 2018) |
| "Children with myasthenia gravis who had not achieved satisfactory improvement or who experienced severe side effects after prednisone therapy were recruited between January 2015 and December 2016 at Tongji Hospital." | 3.85 | Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone. ( Bu, B; Cao, Y; Gui, M; Ji, S; Li, Y; Lin, J; Liu, C, 2017) |
| " All patients were treated successfully with acetylcholinesterase inhibitors (AcheI) and prednisone with two exhibiting full remission of their symptoms, while the remaining exhibited mild residual diplopia." | 3.80 | Double seronegative myasthenia gravis with low density lipoprotein-4 (LRP4) antibodies presenting with isolated ocular symptoms. ( Dervenoulas, G; Kokotis, P; Tsivgoulis, G; Tzartos, JS; Tzartos, SJ; Voumvourakis, KI; Zompola, C, 2014) |
| " We hypothesized that a long-term low-dose prednisone regimen for ocular myasthenia gravis (OMG) would have a low rate of major side effects." | 3.78 | Safety of prednisone for ocular myasthenia gravis. ( Bruce, BB; Kupersmith, MJ, 2012) |
| "Two recent randomized, controlled trials failed to demonstrate a benefit of mycophenolate mofetil (MMF) over prednisone in the treatment of myasthenia gravis (MG)." | 3.76 | Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. ( Alpers, J; Burns, TM; Conaway, MR; Hehir, MK; Sanders, DB; Sawa, M, 2010) |
| "We previously reported that prednisone reduced the frequency of generalized myasthenia (GMG) and controlled diplopia without major adverse effects at 2 years in patients with ocular myasthenia gravis (OMG)." | 3.75 | Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. ( Kupersmith, MJ, 2009) |
| " Here we show that the number of Treg cells in the blood is significantly lower in untreated myasthenia gravis patients than in age-matched healthy subjects, whereas it is normal or elevated in patients on immunosuppressive therapy (prednisone frequently associated with azathioprine)." | 3.73 | Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. ( Battaglia, A; Buzzonetti, A; Ciaraffa, F; Evoli, A; Fattorossi, A; Scambia, G, 2005) |
| " The authors evaluated the efficacy of prednisone and pyridostigmine in reducing diplopia, ocular motor dysfunction, and ptosis in patients with OMG." | 3.73 | Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. ( Kupersmith, MJ; Ying, G, 2005) |
| "To assess the effect of oral corticosteroid therapy on the frequency of development of generalized myasthenia gravis within 2 years, the incidence of thymoma, and the amount of edrophonium needed for a positive test result in patients with ocular myasthenia gravis." | 3.72 | Development of generalized disease at 2 years in patients with ocular myasthenia gravis. ( Homel, P; Kupersmith, MJ; Latkany, R, 2003) |
| " We report a unique case of a 64-year-old woman who had been on prednisone monotherapy for the treatment of myasthenia gravis and subsequently developed cryptococcal cellulitis." | 3.72 | Cryptococcal cellulitis in a patient on prednisone monotherapy for myasthenia gravis. ( Beaty, S; Colome-Grimmer, MI; Dotson, AD; Lafleur, L; LaForte, RA, 2004) |
| "Prednisone therapy and intravenous gamma globulin may be helpful in patients with generalized myasthenia gravis complicating HIV infection." | 3.70 | Seronegative myasthenia gravis and human immunodeficiency virus infection: response to intravenous gamma globulin and prednisone. ( Strong, J; Zochodne, DW, 1998) |
| "Patients with severe myasthenia gravis may safely be treated with plasma exchange in combination with prednisone." | 3.69 | [Favorable results of plasmapheresis in severe myasthenia gravis]. ( Blom, RJ; Kuks, JB; Oosterhuis, HJ; Westerterp-Maas, A, 1997) |
| "We studied the long-term outcome of prednisone therapy in 104 patients with myasthenia gravis (MG)." | 3.68 | Long-term results of corticosteroid therapy in patients with myasthenia gravis. ( Batocchi, AP; Evoli, A; Lo Monaco, M; Palmisani, MT; Tonali, P, 1992) |
| "The influence of age at onset, sex, duration of disease and severity degree on the response to therapy have been evaluated in 30 patients with myasthenia gravis treated with prednisone." | 3.68 | [Predictive factors of the response to treatment of myasthenia gravis with prednisone]. ( Illa, I; Pradas, J, 1990) |
| "One hundred sixteen patients, aged 8 to 82 years, with myasthenia gravis were treated with prednisone, 60 to 80 mg daily, until the onset of improvement, followed by lower-dose alternate-day therapy of several years' duration." | 3.67 | Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. ( Coslett, HB; Johns, TR; Pascuzzi, RM, 1984) |
| "Twenty-four patients with myasthenia gravis were treated with azathioprine." | 3.67 | Azathioprine in the treatment of myasthenia gravis. ( Cornblath, DR; Lisak, RP; Parry, GJ; Schatz, NJ; Witte, AS, 1984) |
| "In a selected group of 69 patients with myasthenia gravis treated with prednisone, the factors were studied that might have influenced the reoccurrence or exacerbation of clinical signs after initial improvement in two-thirds of the patients." | 3.67 | Factors influencing the relapse risk at steroid dose reduction in myasthenia gravis. ( Oosterhuis, HJ; Scherpbier, HJ, 1987) |
| "In patients with myasthenia gravis who received single doses of prednisone orally (40 to 100 mg), we found acute inhibition of neuromuscular function as manifest by increased decremental responses to repetitive nerve stimulation, reduced twitch tension, and lowered maximum voluntary contraction strength." | 3.67 | Prednisone-induced worsening of neuromuscular function in myasthenia gravis. ( Miller, RG; Milner-Brown, HS; Mirka, A, 1986) |
| " Degree of weakness, duration of illness, use of prednisone, and history of thymectomy or thymoma did not affect the response to intravenous immunoglobulin." | 3.67 | High-dose intravenous immunoglobulin in the management of myasthenia gravis. ( Arsura, EL; Bick, A; Brunner, NG; Grob, D; Namba, T, 1986) |
| " They started approximately 4 months after the patient had begun a regimen of prednisone and cyclophosphamide for myasthenia gravis." | 3.67 | Multiple dermatofibromas in a patient with myasthenia gravis treated with prednisone and cyclophosphamide. ( Bargman, HB; Fefferman, I, 1986) |
| "A 40-year-old woman with clinical and laboratory features of myasthenia gravis, hyperthyroidism, and polymyositis responded to treatment with prednisone alone." | 3.66 | Prednisone use in concurrent autoimmune diseases. ( Harati, Y; Patten, BM, 1979) |
| "The effect of 310 courses of corticotropin, methylprednisolone, prednisone, and dexamethasone were studied in 62 patients with generalized myasthenia gravis who were poorly responsive to anticholinesterase medication and most of whom required assisted respiration." | 3.65 | Corticotropin and corticosteroids in generalized myasthenia gravis: comparative studies and role in management. ( Berger, CL; Brunner, NG; Grob, D; Namba, T, 1976) |
| "Favorable results were obtained in 30 patients with myasthenia gravis treated initially with high daily doses of prednisone and subsequently maintained on lower doses for a protracted period." | 3.65 | Long-term administration of corticosteroids in myasthenia gravis. ( Campa, JF; Johns, TR; Mann, JD, 1976) |
| "Plasmapheresis combined with prednisone and azathioprine therapy produced striking clinical improvement in five patients with myasthenia gravis who still had moderate to severe disability despite thymectomy, high-dose prednisone therapy and optimal doses of cholinesterase inhibitors." | 3.65 | Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. ( Cassel, CK; Dau, PC; Denys, EH; Lindstrom, JM; Shev, EE; Spitler, LE, 1977) |
| "To determine the effects of alternate-day prednisone therapy on respiratory function in myasthenia gravis, eight patients were evaluated during "days on" and "days off" prednisone." | 3.65 | Effects of alternate-day prednisone therapy on respiratory function in myasthenia gravis. ( Brahim, SA; Newball, HH, 1976) |
| "Myasthenia gravis is an autoimmune neuromuscular disorder caused by antibodies directed against proteins present at the post-synaptic surface of neuromuscular junction resulting in weakness." | 2.79 | Serum metabolomic response of myasthenia gravis patients to chronic prednisone treatment. ( Cheema, A; Kaminski, HJ; Kusner, LL; Sengupta, M, 2014) |
| "Prednisone was given at the lowest dose to manage MG symptoms and adjusted as required according to protocol." | 2.76 | A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. ( Badri, M; Bateman, K; Heckmann, JM; Rawoot, A; Renison, R, 2011) |
| "Thymectomy is a standard treatment of myasthenia gravis (MG)." | 2.73 | Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study. ( Armengol, M; Azem, J; Buera, M; Fort, JM; Gamez, J; López-Cano, M; Ponseti, JM; Vilallonga, R, 2007) |
| "EA warming therapy combined with western medicine has a significant therapeutic effect on myasthenia gravis." | 2.73 | [Electroacupuncture warming therapy combined with western medicine for treatment of myasthenia gravis and effect on IL-4 level in the patients]. ( Cui, X; Feng, J; Wang, SH, 2007) |
| "To describe a case of coincident Castleman's disease and myasthenia gravis that initially presented as rapidly progressive dysphagia and dysphonia and to review the unique pathophysiology of these two uncommon diagnoses." | 2.72 | Dysphagia and Dysphonia, a Pairing of Symptoms Caused by an Unusual Pair of Diseases: Castleman's Disease and Myasthenia Gravis. ( Abdelmeguid, A; Berry, GJ; Dewan, K; Rojansky, R, 2021) |
| "Thymectomy is a standard treatment of myasthenia gravis (MG)." | 2.72 | Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis. ( Armengol, M; Azem, J; Fort, JM; Gamez, J; López-Cano, M; Ponseti, JM; Vilallonga, R, 2006) |
| "We report favorable results of the long term use of mycophenolate in the treatment of three patients with myasthenia gravis (MG), two patients with chronic inflammatory demyelinating polyneuropathy (CIDP), one patient with secondary polymyositis (PM), and one patient with inclusion body myositis (IBM)." | 2.70 | Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. ( Bradley, WG; Mowzoon, N; Sussman, A, 2001) |
| "Myasthenia gravis is uncommon in children." | 2.48 | Myasthenia gravis in Jamaican children: a 12-year institutional review. ( Forrester, S; Gray, R; Melbourne Chambers, R; Tapper, J; Trotman, H, 2012) |
| "Transitory neonatal myasthenia gravis (TNMG) was diagnosed in 30% infants." | 2.41 | Myasthenia gravis in pregnancy: report on 69 cases. ( Djelmis, J; Ivanisevic, M; Mayer, D; Sostarko, M, 2002) |
| "Myasthenia gravis is an autoimmune disease mediated by auto-antibodies direct against the nicotinic receptor for acetylcholine." | 2.41 | Plasma exchange for myasthenia gravis. ( Chevret, S; Gajdos, P; Toyka, K, 2002) |
| "Advances in the treatment of myasthenia gravis (MG) have improved quality of life and prognosis for the majority of patients." | 1.91 | A series of patients with refractory myasthenia gravis. ( Díaz-Maroto, I; Garcia-Garcia, J; Martínez-Martín, A; Pardal-Fernández, JM; Segura, T, 2023) |
| "Myasthenia gravis is an autoimmune condition affecting the neuromuscular junction and causing muscle weakness along with fatigue (myasthenia)." | 1.91 | Diplopia in a patient presenting with "blurred vision": a case report. ( Harrison, A; Mudhar, O; Rampal, M; Yoo, J, 2023) |
| "For children with OMG, the addition of various immunosuppressants can reduce the dosage of GC and adverse reactions." | 1.91 | [Clinical effect of different immunosuppressive treatment regimens in children with ocular myasthenia gravis: a retrospective analysis]. ( Chen, H; Chen, Y; Huang, ZX; Wang, RY; Zhong, JM, 2023) |
| "This study evaluated the clinical efficacy of leflunomide combined with low-dose prednisone (0." | 1.91 | Clinical evaluation of efficacy of leflunomide combined with low-dose prednisone for treatment of myasthenia gravis. ( Chen, J; Huang, X; Liu, W; Lu, Y; Ou, C; Qiu, L; Ran, H; Yang, W, 2023) |
| " We evaluated adverse side effects (ASEs) of corticosteroid treatment in patients with gMG." | 1.62 | Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis. ( Govindarajan, R; Johnson, S; Katyal, N; Narula, N, 2021) |
| "Azathioprine (AZA) has been shown to be effective for MG with a significant steroid-sparing activity, although burdened by side effects." | 1.62 | Methotrexate as a Steroid-Sparing Agent in Myasthenia Gravis: A Preliminary Retrospective Study. ( Bonanno, C; Brizzi, T; Lupica, A; Musumeci, O; Nicocia, G; Pugliese, A; Rodolico, C; Toscano, A; Trimarchi, G, 2021) |
| " Serious adverse events (SAEs) were similar between older and younger patients (21." | 1.62 | Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients ≥65 years old. ( Amato, AA; David, WS; Doughty, CT; Guidon, AC; Suh, J, 2021) |
| "Thymectomy is considered an effective treatment for myasthenia gravis but the benefit is not immediate." | 1.56 | [Thymectomy in thymomatous and non-thymomatous myasthenia gravis: analysis of a cohort of 46 patients]. ( Alba-Isasi, MT; Arroyo-Tristán, A; Cabrera-Maqueda, JM; Hernández, R; Morales-Ortiz, A, 2020) |
| "Highest contributors were infections (30%) and medications that may worsen MG (19%), with 24% unattributed." | 1.51 | Factors associated with acute exacerbations of myasthenia gravis. ( Deroche, CB; Govindarajan, R; Gummi, RR; Kukulka, NA, 2019) |
| "Patients diagnosed with ocular myasthenia gravis (MG) and mitral valve disease represent a significant perioperative management problem, especially for the anaesthesiologist, due to complex inter-actions between the disease, drugs to treat the disease, and anaesthetic agents, such as neuromuscu-lar blocking agents (NMBAs)." | 1.51 | Mitral Valve Replacement with Thymectomy in a Patient with Ocular Myasthenia Gravis: Case Report. ( Chioncel, O; Filipescu, D; Geana, RC; Iliescu, VA; Radu, R; Sorostinean, D; Stefan, M; Stiru, O, 2019) |
| " Also, the daily prednisone dosage was significantly decreased in 20/24 patients across all three serotype groups." | 1.51 | Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis. ( Corse, AM; Doherty, L; Roda, RH, 2019) |
| "Seventy-six of 87 cases had persistent ophthalmoparesis." | 1.48 | Myasthenic ophthalmoparesis: Time To resolution after initiating immune therapies. ( Europa, TA; Heckmann, JM; Nel, M, 2018) |
| "Intermittent diplopia with subtle ophthalmoparesis was the most common complaint, ptosis was generally symmetrical and conjugated gaze paresis occurred in 35% of the patients." | 1.46 | Pattern of ocular involvement in myasthenia gravis with MuSK antibodies. ( Alboini, PE; Bartoccioni, E; Damato, V; Evoli, A; Iorio, R, 2017) |
| " QMGS, MMT and MG-ADL were significantly improved and the average steroid dosage reduction was 43% (p=0." | 1.46 | Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis. ( Huang, Y; Jing, S; Lu, J; Pang, S; Quan, C; Song, J; Song, Y; Xi, J; Zhao, C; Zhou, L, 2017) |
| "Myasthenia gravis is an autoimmune disease of the neuromuscular junction, commonly affecting the ocular muscles." | 1.43 | Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis. ( Feuer, WJ; Gratton, SM; Herro, AM; Lam, BL, 2016) |
| "Leflunomide is an effective drug used in the treatment of rheumatoid arthritis." | 1.43 | Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study. ( Chen, P; Deng, J; Feng, H; Liu, W; Luo, Y; Ou, C; Qiu, L, 2016) |
| "Advances in the treatment of myasthenia gravis have reduced mortality and morbidity and improved the quality of life in these patients." | 1.38 | Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature. ( Abdwani, R; Al Futaisi, A; Koul, R, 2012) |
| "Sweet syndrome is a reactive, sterile, pustular dermatosis that occurs in association with infection, malignancy, or connective tissue disease or in response to the use of certain medications." | 1.35 | Sweet syndrome as a manifestation of azathioprine hypersensitivity. ( Brunner, KL; El-Azhary, RA; Gibson, LE, 2008) |
| "Records of 50 patients treated for myasthenia gravis at Children's Memorial Hospital, Chicago, were reviewed." | 1.35 | Graded response to thymectomy in children with myasthenia gravis. ( McRae, W; Millichap, JG; Tracy, MM, 2009) |
| "We report a woman with Parkinson's disease and head drop not due to cervical dystonia (a common cause of antecollis in parkinsonisms)." | 1.35 | Myasthenia gravis: an unrecognized cause of head drop in Parkinson's disease. ( Bentivoglio, AR; Evoli, A; Fasano, A; Piano, C; Tonali, PA, 2008) |
| "Mild limb weakness with severe muscle atrophy and diffuse muscle twitches were observed." | 1.34 | Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome. ( Blesa, R; Dalmau, J; Díaz-Manera, J; Gallardo, E; Illa, I; Juárez, C; Martínez-Domeño, A; Martínez-Ramírez, S; Rojas-García, R, 2007) |
| "If myasthenia gravis is not a usual complication of interferon therapy, several cases have been described with the use of theses molecules in the treatment of hepatitis C, cancer or multiple sclerosis." | 1.34 | [Development of a myasthenia crisis during interferon treatment for chronic C hepatitis]. ( Casassus-Buihle, D; Chauveau, E; Fraudin, A; Oddes, B; Reffet, A; Terrier, F, 2007) |
| "Hypereosinophilia has been associated with a wide variety of systemic disorders, including myositis." | 1.33 | Eosinophilia, myositis, and myasthenia gravis associated with a thymoma. ( Avni, I; Buchman, AS; Sadeh, M; Sharabi, Y, 2006) |
| " A high daily dosage of prednisone relative to body weight was found to be neither a predictor of exacerbation nor a predictor of early improvement in bivariate correlation analysis." | 1.33 | Clinical predictors of steroid-induced exacerbation in myasthenia gravis. ( Bae, JS; Go, SM; Kim, BJ, 2006) |
| "Fifty percent of ocular myasthenia gravis (OMG) patients will progress to generalized myasthenia, 90% within 3 years from the onset of ocular symptoms." | 1.32 | The effect of prednisone on the progression from ocular to generalized myasthenia gravis. ( Goldstein, JM; Knorr, AM; Lesser, RL; Monsul, NT; Patwa, HS, 2004) |
| "We conclude that as for the medical treatment of myasthenia gravis azathioprine plus steroid improves the outcome; and for the surgical treatment, early thymectomy should be performed in all generalize myasthenia patients." | 1.32 | Myasthenia gravis: how to treat? ( Akpinar, A; Karlikaya, G; Okay, T; Tireli, H; Tutkavul, K, 2004) |
| "Myasthenia gravis is a life-threatening disease as evidenced by the death of one of our patients." | 1.31 | The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children. ( Buncic, JR; Mullaney, P; Smith, R; Vajsar, J, 2000) |
| "The case of a patient with fatigable diplopia and ptosis 3 years after removal of a large-cell lung carcinoma is presented." | 1.31 | Myasthenia gravis with a paraneoplastic marker. ( Leavitt, JA, 2000) |
| "We describe a patient with dysphagia who was diagnosed at different points in time with all these three rare conditions." | 1.31 | Dysphagia with multiple autoimmune disease. ( Heller, I; Isakov, A; Kornizky, Y; Shapira, I; Topilsky, M, 2000) |
| "Myasthenia gravis is characterised by muscle weakness and fatigability, particularly of the facial and extremity muscles, deteriorating during the day." | 1.31 | A severe case of myasthenia gravis during pregnancy. ( Andriessen, P; Brölmann, HA; Dellemijn, PL; Hansen, EC; Oei, SG; Pijnenborg, JM, 2000) |
| " Remission, pharmacological remission, and marked improvement with reduction in drug dosage were considered good results." | 1.31 | Clinical characteristics and prognosis of myasthenia gravis in older people. ( Batocchi, AP; Di Schino, C; Evoli, A; Minisci, C; Tonali, P, 2000) |
| "Ocular myasthenia gravis is a localized form of myasthenia in which only the extra-ocular muscles are clinically affected, namely the levator palpebrae superioris and orbicularis oculi." | 1.30 | [Ocular myasthenia: clinical course and strategies for treatment]. ( Ara, JR; Capablo, JL; Marzo, ME; Pérez López-Fraile, I; Usón, M, 1998) |
| "Relapses are frequent after treatment withdrawal." | 1.30 | [Treatment of myasthenia: role of corticoids and immunosuppressive agents]. ( Gajdos, P, 1999) |
| "Myasthenia gravis is an autoimmune disease that is associated with antibodies to acetylcholine receptors." | 1.29 | Myasthenia gravis and scleroderma. ( Ajmani, HS; Bhalla, R; Lazarevic, MB; Skosey, JL; Swedler, WI, 1993) |
| "Prednisone was added 2 months after thymectomy due to continued worsening and development of oropharyngeal weakness." | 1.29 | Single fiber electromyography in myasthenia gravis during pregnancy. ( Massey, JM; Sanders, DB, 1993) |
| "Prednisone was used in 17 cases, high dosage of methylprednisolone in 8 (in one case twice), azathioprine in 11 and cyclophosphamide in 10." | 1.28 | Immunosuppressive treatment for juvenile myasthenia gravis. ( Badurska, B; Ryniewicz, B; Strugalska, H, 1992) |
| "Maternal myasthenia gravis has been associated with the presence of neonatal myasthenia and sometimes fatal congenital anomalies." | 1.28 | Treatment of antenatal myasthenia gravis. ( Abuelo, DN; Carr, SR; Clark, D; Gilchrist, JM, 1991) |
| "The myasthenia gravis was controlled with pyridostigmine." | 1.28 | Widespread pulmonary fibrosis as a major clinical manifestation of chronic graft-versus-host disease. ( Atkinson, K; Biggs, J; Bryant, D; Delprado, W, 1989) |
| "Most autoimmune diseases are responsive to corticosteroids administered in dosages sufficient to shut off the inflammatory process." | 1.27 | Corticosteroids in autoimmune disease. ( Fauci, AS, 1983) |
| " Anticholinesterase medication (nine patients) and corticosteroid dosage (six patients) had been kept constant for a 2-month period." | 1.27 | Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis. ( Arsura, EL; Bick, A; Brunner, NG; Grob, D, 1988) |
| " In patients without clinical remission immunosuppressive drugs were prescribed in different schedule; the greater percentage of pharmacological remissions with less adverse effects was obtained with administration of prednisone 50-75 mg/die initially, than gradually reduced to smaller dosage in alternate day, associated to azathioprine." | 1.27 | Myasthenia gravis treatment: twelve years experience on 110 patients. ( Jann, S; Premoselli, S; Scarlato, G; Valli, G, 1987) |
| "We studied two patients, one with systemic lupus erythematosus and the other with myasthenia gravis, both of whom had coexistent blepharospasm." | 1.27 | Blepharospasm and autoimmune diseases. ( Jankovic, J; Patten, BM, 1987) |
| "Prednisone is an alternative form of treatment for ELS, although the mechanism for its action is unclear." | 1.26 | Eaton-Lambert myasthenic syndrome: long-term treatment of three patients with prednisone. ( Rothner, AD; Streib, EW, 1981) |
| "Myasthenia gravis is a chronic disease characterized by a fluctuating weakness of voluntary muscles, with a preference for the muscles innervated by the cranial nerves." | 1.26 | The ocular signs and symptoms of myasthenia gravis. ( Oosterhuis, HJ, 1982) |
| "20 patients with myasthenia gravis (MG), refractory to anticholinesterase and steroid therapy, underwent plasma exchange therapy combined with immunosuppressive drugs and lymphocytapheresis." | 1.26 | Plasma exchange combined with cytotoxic drugs and lymphocytapheresis for myasthenia gravis. ( Cornelio, F; Forlani, G; Garelli, S; Pelucchetti, D; Valbonesi, M; Zerbi, D, 1982) |
| " Approximately half the patients were being treated with an alternate day regime of prednisone, receiving high dosage one day and low the next." | 1.26 | Psychiatric effects of alternate day steroid therapy. ( Cordess, C; Drachman, D; Folstein, M, 1981) |
| "Oral Prednisone was nearly always preferred: alternate-day high single dose (75 to 115 mg) has given good results in most cases even if in some cases a small dose was required in the "off day"; inversely a lower alternate-day or daily dose was often sufficient." | 1.26 | Treatment of myasthenia gravis. Report on 139 patients. ( Crucitti, F; David, P; Evoli, A; Scoppetta, C; Tonali, P; Vaccario, ML, 1979) |
| " Long-term administration of steroids, with the attendant complication of growth retardation, is avoided." | 1.26 | Effective treatment of infantile myasthenia gravis by combined prednisone and thymectomy. ( Lewis, JE; McGarry, JD; Sarnat, HB, 1977) |
| "Myasthenia gravis is a disorder that most commonly affects young adults but occasionally appears in the elderly." | 1.26 | Essentials in the management of myasthenia gravis. ( Galdi, AP, 1978) |
| "The results of treatment of myasthenia gravis in 12 patients are reported." | 1.25 | [Corticosteroids in the treatment of myasthenia gravis. Study of 12 cases with review of the literature]. ( Lamartine de Assis, J, 1975) |
| "Ocular myasthenia gravis was managed with an anticholinesterase agent in combination with oral corticosteroids that provided additional control." | 1.25 | Ocular myasthenia gravis and Hashimoto's thyroiditis. ( Osher, RH; Smith, JL, 1975) |
| "As the use of corticosteroids in the treatment of myasthenia gravis becomes more common, this association can be expected to occur more often." | 1.25 | Corticosteroid-induced mediastinal widening in myasthenia gravis. ( Strother, CM, 1975) |
| " Radical excision of the tumor, if possible, and the remaining thymus, high dosage alternate day prednisone, and radiation therapy, if indicated, seem the treatments of choice." | 1.25 | Myasthenia gravis and invasive thymoma: a 20-year experience. ( Brown, WJ; Goldman, AJ; Herrmann, C; Keesey, JC; Mulder, DG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 169 (42.89) | 18.7374 |
| 1990's | 44 (11.17) | 18.2507 |
| 2000's | 72 (18.27) | 29.6817 |
| 2010's | 70 (17.77) | 24.3611 |
| 2020's | 39 (9.90) | 2.80 |
| Authors | Studies |
|---|---|
| Johnson, S | 1 |
| Katyal, N | 1 |
| Narula, N | 1 |
| Govindarajan, R | 3 |
| Rodolico, C | 1 |
| Bonanno, C | 1 |
| Brizzi, T | 1 |
| Nicocia, G | 1 |
| Trimarchi, G | 1 |
| Lupica, A | 1 |
| Pugliese, A | 1 |
| Musumeci, O | 1 |
| Toscano, A | 1 |
| Wang, S | 2 |
| Yang, H | 3 |
| Guo, R | 1 |
| Wang, L | 1 |
| Zhang, Y | 7 |
| Lv, J | 2 |
| Zhao, X | 2 |
| Zhang, J | 2 |
| Fang, H | 2 |
| Zhang, Q | 5 |
| Yang, J | 2 |
| Cui, X | 3 |
| Gao, P | 1 |
| Chang, T | 2 |
| Gao, F | 2 |
| Moradi, LA | 1 |
| Clark, CA | 1 |
| Schneider, CS | 1 |
| Deshane, AS | 1 |
| Dobelbower, MC | 1 |
| Di, L | 1 |
| Shen, F | 1 |
| Wen, X | 1 |
| Lu, Y | 2 |
| Zhu, W | 1 |
| Wang, M | 1 |
| Da, Y | 1 |
| Wu, H | 1 |
| Chen, L | 1 |
| Zhou, X | 1 |
| Wu, Y | 2 |
| Yan, Y | 1 |
| Zhu, Y | 1 |
| Zhao, C | 2 |
| Xue, Q | 1 |
| Heckmann, JM | 10 |
| Caifeng, S | 1 |
| Jingsheng, Z | 1 |
| Yi, L | 1 |
| Xueshi, H | 1 |
| Zhanyou, W | 1 |
| Haiou, P | 1 |
| Wenjun, Q | 1 |
| Bi, Z | 3 |
| Cao, Y | 4 |
| Gui, M | 4 |
| Lin, J | 5 |
| Li, Y | 8 |
| Ji, S | 4 |
| Bu, B | 5 |
| Hehir, MK | 3 |
| Prado, MB | 1 |
| Adiao, KJB | 1 |
| Garcia-Garcia, J | 1 |
| Díaz-Maroto, I | 1 |
| Martínez-Martín, A | 1 |
| Pardal-Fernández, JM | 1 |
| Segura, T | 1 |
| Wu, T | 1 |
| Wang, B | 1 |
| Xu, P | 1 |
| Lv, Z | 1 |
| Zhang, D | 1 |
| Lu, J | 2 |
| Wu, L | 2 |
| Liu, M | 2 |
| Chen, Z | 1 |
| Lan, T | 1 |
| Wang, J | 1 |
| Ge, H | 1 |
| Gao, H | 1 |
| Yang, M | 1 |
| Zhan, J | 1 |
| Zhang, M | 1 |
| Zhang, L | 1 |
| Zhou, S | 1 |
| Li, W | 1 |
| Harrison, A | 1 |
| Mudhar, O | 1 |
| Yoo, J | 1 |
| Rampal, M | 1 |
| Sikorski, P | 1 |
| Cheema, M | 1 |
| Wolfe, GI | 10 |
| Kusner, LL | 2 |
| Aban, I | 3 |
| Kaminski, HJ | 10 |
| Wang, RY | 1 |
| Chen, H | 1 |
| Huang, ZX | 1 |
| Chen, Y | 1 |
| Zhong, JM | 1 |
| Gummi, RR | 1 |
| Kukulka, NA | 1 |
| Deroche, CB | 1 |
| de Meel, RHP | 1 |
| Tannemaat, MR | 1 |
| Verschuuren, JJGM | 2 |
| Stiru, O | 1 |
| Stefan, M | 1 |
| Geana, RC | 1 |
| Sorostinean, D | 1 |
| Radu, R | 1 |
| Filipescu, D | 1 |
| Chioncel, O | 1 |
| Iliescu, VA | 1 |
| Xu, L | 1 |
| Castro, D | 1 |
| Reisch, JS | 1 |
| Iannaccone, ST | 1 |
| Cabrera-Maqueda, JM | 1 |
| Alba-Isasi, MT | 1 |
| Hernández, R | 1 |
| Arroyo-Tristán, A | 1 |
| Morales-Ortiz, A | 1 |
| Bortone, F | 1 |
| Scandiffio, L | 1 |
| Marcuzzo, S | 1 |
| Bonanno, S | 1 |
| Frangiamore, R | 1 |
| Motta, T | 1 |
| Antozzi, C | 1 |
| Mantegazza, R | 3 |
| Cavalcante, P | 1 |
| Bernasconi, P | 1 |
| Gronseth, GS | 1 |
| Barohn, R | 1 |
| Narayanaswami, P | 1 |
| McPherson, T | 2 |
| Duda, PW | 1 |
| Farzaneh-Far, R | 1 |
| Cutter, G | 3 |
| Lee, I | 2 |
| Yuen, C | 1 |
| Soliven, B | 2 |
| Rezania, K | 2 |
| Liu, D | 1 |
| Hong, X | 1 |
| Sun, H | 1 |
| Zheng, Y | 1 |
| Yang, B | 1 |
| Wang, W | 1 |
| Kuo, HC | 3 |
| Aban, IB | 4 |
| Cutter, GR | 4 |
| Sussman, J | 1 |
| Ströbel, P | 4 |
| Oger, J | 4 |
| Cea, G | 1 |
| Evoli, A | 16 |
| Nix, W | 3 |
| Ciafaloni, E | 4 |
| Antonini, G | 4 |
| Witoonpanich, R | 3 |
| King, JO | 3 |
| Beydoun, SR | 3 |
| Chalk, CH | 3 |
| Barboi, AC | 3 |
| Amato, AA | 4 |
| Shaibani, AI | 3 |
| Katirji, B | 3 |
| Lecky, BRF | 2 |
| Buckley, C | 3 |
| Vincent, A | 6 |
| Dias-Tosta, E | 5 |
| Yoshikawa, H | 4 |
| Waddington-Cruz, M | 3 |
| Pulley, MT | 4 |
| Rivner, MH | 3 |
| Kostera-Pruszczyk, A | 3 |
| Pascuzzi, RM | 4 |
| Jackson, CE | 3 |
| Verschuuren, JJG | 1 |
| Massey, JM | 4 |
| Kissel, JT | 4 |
| Werneck, LC | 3 |
| Benatar, M | 8 |
| Barohn, RJ | 8 |
| Tandan, R | 5 |
| Mozaffar, T | 5 |
| Conwit, R | 4 |
| Minisman, G | 4 |
| Sonett, JR | 3 |
| Singh, S | 1 |
| Díez-Porras, L | 1 |
| Homedes, C | 1 |
| Alberti, MA | 1 |
| Vélez-Santamaría, V | 1 |
| Casasnovas, C | 1 |
| Abdelmeguid, A | 1 |
| Rojansky, R | 1 |
| Berry, GJ | 1 |
| Dewan, K | 1 |
| Shah, YS | 1 |
| Henderson, AD | 1 |
| Carey, AR | 1 |
| Ziobro, AS | 1 |
| LaPlante, RL | 1 |
| DeMari, SR | 1 |
| Clark, LM | 1 |
| Kingsley, DJ | 1 |
| Smith, AJ | 1 |
| Dang, T | 1 |
| Macwan, S | 1 |
| Dasanu, CA | 1 |
| Abuzinadah, AR | 2 |
| Alanazy, MH | 1 |
| Butt, NS | 1 |
| Dimachkie, MM | 4 |
| Verma, R | 1 |
| Kupersmith, MJ | 7 |
| Fisher, KS | 1 |
| Gill, J | 1 |
| Todd, HF | 1 |
| Yang, MB | 1 |
| Lopez, MA | 1 |
| Abid, F | 1 |
| Lotze, T | 1 |
| Shah, VS | 1 |
| Wilf-Yarkoni, A | 1 |
| Lotan, I | 1 |
| Steiner, I | 2 |
| Hellmann, MA | 2 |
| Golding, B | 1 |
| Lee, Y | 1 |
| Golding, H | 1 |
| Khurana, S | 1 |
| Doughty, CT | 1 |
| Suh, J | 1 |
| David, WS | 1 |
| Guidon, AC | 1 |
| Huang, X | 1 |
| Qiu, L | 2 |
| Chen, J | 1 |
| Yang, W | 1 |
| Ou, C | 2 |
| Ran, H | 1 |
| Liu, W | 3 |
| Alboini, PE | 2 |
| Iorio, R | 1 |
| Damato, V | 2 |
| Bartoccioni, E | 4 |
| Gungor-Tuncer, O | 1 |
| Yilmaz, V | 1 |
| Toker, A | 1 |
| Saruhan-Direskeneli, G | 1 |
| Gulsen-Parman, Y | 1 |
| Oflazer-Serdaroglu, P | 1 |
| Deymeer, F | 1 |
| Jing, S | 1 |
| Song, Y | 1 |
| Song, J | 1 |
| Pang, S | 1 |
| Quan, C | 1 |
| Zhou, L | 1 |
| Huang, Y | 2 |
| Xi, J | 1 |
| Liu, C | 2 |
| Wang, X | 1 |
| Xie, L | 1 |
| Peng, J | 1 |
| Zheng, X | 1 |
| Gravino, D | 1 |
| McNierney-Moore, A | 1 |
| Alnosair, E | 1 |
| Algahtani, RM | 1 |
| Europa, TA | 1 |
| Nel, M | 1 |
| Weis, CA | 1 |
| Scharff, C | 1 |
| Grießmann, BW | 1 |
| Deligianni, M | 1 |
| Kayser, K | 1 |
| Marx, A | 3 |
| Zhao, LN | 1 |
| Liang, Y | 1 |
| Fang, XJ | 1 |
| Liu, XM | 1 |
| Jiang, QL | 1 |
| Wang, SS | 1 |
| She, SF | 1 |
| Cao, M | 1 |
| Pan, J | 1 |
| Jiang, Q | 1 |
| Liu, F | 1 |
| Wen, Y | 1 |
| Jabari, D | 1 |
| Jawdat, O | 1 |
| Pasnoor, M | 4 |
| Glenn, M | 1 |
| Herbelin, L | 3 |
| McVey, AL | 1 |
| Clifford, KM | 1 |
| Hobson-Webb, LD | 1 |
| Burns, TM | 3 |
| Barnett, C | 1 |
| Silvestri, NJ | 2 |
| Howard, JF | 2 |
| Visser, A | 1 |
| Crum, BA | 1 |
| Nowak, R | 1 |
| Beekman, R | 2 |
| Kumar, A | 1 |
| Ruzhansky, K | 1 |
| Chen, IA | 1 |
| Laboy, SM | 1 |
| Fellman, MA | 1 |
| Howard, DB | 1 |
| Kolb, NA | 1 |
| Greene, SM | 1 |
| Berrih-Aknin, S | 1 |
| Le Panse, R | 1 |
| Mazia, C | 2 |
| Cea, JG | 2 |
| Jaretzki, A | 4 |
| Newsom-Davis, J | 5 |
| Nakamura, S | 1 |
| Kawaguchi, K | 1 |
| Fukui, T | 1 |
| Hakiri, S | 1 |
| Ozeki, N | 1 |
| Mori, S | 1 |
| Goto, M | 1 |
| Hashimoto, K | 1 |
| Ito, T | 1 |
| Yokoi, K | 1 |
| Jordan, B | 1 |
| Zierz, S | 1 |
| Weber, T | 1 |
| Jordan, K | 1 |
| Li, M | 1 |
| Han, J | 1 |
| Ren, L | 1 |
| Li, Q | 1 |
| Du, Y | 1 |
| Weinberg, M | 1 |
| Cavalcante, JA | 1 |
| Choy, T | 1 |
| Ahmad, S | 1 |
| Roda, RH | 1 |
| Doherty, L | 1 |
| Corse, AM | 1 |
| Abraham, A | 1 |
| Lovblom, LE | 1 |
| Bril, V | 2 |
| Tung, CI | 1 |
| Chao, D | 1 |
| Al-Zubidi, N | 1 |
| Yalamanchili, M | 1 |
| Lee, AG | 2 |
| Wang, H | 1 |
| Su, Z | 1 |
| Luo, C | 1 |
| Feng, H | 2 |
| Fang, W | 1 |
| Du, C | 1 |
| Deng, J | 2 |
| Yu, F | 1 |
| Levin, MH | 1 |
| Gopal, PP | 1 |
| Galetta, SL | 1 |
| Tsivgoulis, G | 2 |
| Dervenoulas, G | 2 |
| Tzartos, SJ | 2 |
| Zompola, C | 2 |
| Papageorgiou, SG | 1 |
| Voumvourakis, K | 1 |
| Auret, J | 1 |
| Abrahams, A | 1 |
| Prince, S | 1 |
| Morgenstern, M | 1 |
| Singas, E | 1 |
| Zleik, B | 1 |
| Greenberg, H | 1 |
| Sengupta, M | 1 |
| Cheema, A | 1 |
| Kokotis, P | 1 |
| Tzartos, JS | 1 |
| Voumvourakis, KI | 1 |
| Benjamin, B | 1 |
| Zaltzman, R | 1 |
| Shpitz, B | 1 |
| Gordon, CR | 1 |
| Avital, S | 1 |
| Gratton, SM | 1 |
| Herro, AM | 1 |
| Feuer, WJ | 1 |
| Lam, BL | 1 |
| Chen, P | 1 |
| Luo, Y | 1 |
| Punga, T | 1 |
| Lewandowska, M | 1 |
| Punga, AR | 1 |
| Belliveau, MJ | 1 |
| Oestreicher, JH | 1 |
| He, J | 1 |
| Nations, S | 2 |
| Wang, AK | 1 |
| Elsheikh, BH | 1 |
| Saperstein, D | 1 |
| Shaibani, JA | 1 |
| Jackson, C | 1 |
| Swenson, A | 1 |
| Goyal, N | 1 |
| David, W | 1 |
| Wicklund, M | 1 |
| Pulley, M | 1 |
| Becker, M | 1 |
| Pazcuzzi, R | 1 |
| Simpson, E | 1 |
| Rosenfeld, J | 1 |
| Statland, JM | 1 |
| Modrego, PJ | 1 |
| Arribas, J | 1 |
| Ropper, AH | 1 |
| Lecky, BR | 1 |
| Garcia Ramos, GS | 1 |
| Verschuuren, JJ | 1 |
| Odenkirchen, J | 1 |
| Sudulagunta, SR | 1 |
| Sepehrar, M | 1 |
| Sodalagunta, MB | 1 |
| Settikere Nataraju, A | 1 |
| Bangalore Raja, SK | 1 |
| Sathyanarayana, D | 1 |
| Gummadi, S | 1 |
| Burra, HK | 1 |
| Bateman, K | 2 |
| Kelkar, P | 1 |
| Cai, G | 1 |
| He, D | 1 |
| Dai, Q | 1 |
| Xu, Z | 1 |
| Chu, L | 1 |
| Sarkhy, A | 1 |
| Persad, R | 1 |
| Tarnopolsky, M | 1 |
| Rowland, LP | 1 |
| Sylva, M | 1 |
| van der Kooi, AJ | 1 |
| Grolman, W | 1 |
| Ponseti, JM | 5 |
| Gamez, J | 3 |
| Vilallonga, R | 4 |
| Ruiz, C | 1 |
| Azem, J | 4 |
| López-Cano, M | 4 |
| Armengol, M | 5 |
| El-Azhary, RA | 1 |
| Brunner, KL | 1 |
| Gibson, LE | 1 |
| Rinaldi, C | 1 |
| Russo, CV | 1 |
| Filla, A | 1 |
| De Michele, G | 1 |
| Marano, E | 1 |
| Tracy, MM | 1 |
| McRae, W | 1 |
| Millichap, JG | 1 |
| Dubal, DB | 1 |
| Mueller, S | 1 |
| Ruben, BS | 1 |
| Engstrom, JW | 1 |
| Josephson, SA | 1 |
| Cucurachi, L | 1 |
| Cattaneo, L | 1 |
| Gemignani, F | 1 |
| Pavesi, G | 1 |
| Dunand, M | 1 |
| Botez, SA | 1 |
| Borruat, FX | 1 |
| Roux-Lombard, P | 1 |
| Spertini, F | 1 |
| Kuntzer, T | 1 |
| Zebardast, N | 1 |
| Patwa, HS | 2 |
| Novella, SP | 1 |
| Goldstein, JM | 2 |
| Trivedi, J | 1 |
| McVey, A | 1 |
| Dimachkie, M | 1 |
| Kissel, J | 1 |
| Walsh, R | 1 |
| Amato, A | 1 |
| Hungs, M | 1 |
| Chui, L | 1 |
| Goldstein, J | 1 |
| Novella, S | 1 |
| Burns, T | 1 |
| Phillips, L | 1 |
| Claussen, G | 1 |
| Young, A | 1 |
| Bertorini, T | 1 |
| Oh, S | 1 |
| Allen, JA | 1 |
| Scala, S | 1 |
| Jones, HR | 1 |
| Karmon, Y | 1 |
| Blum, S | 1 |
| Levite, R | 1 |
| Barenboim, E | 1 |
| Gadoth, N | 1 |
| Alpers, J | 1 |
| Conaway, MR | 1 |
| Sawa, M | 1 |
| Sanders, DB | 5 |
| Klehmet, J | 1 |
| Dudenhausen, J | 1 |
| Meisel, A | 1 |
| Abbott, SA | 1 |
| Rigamonti, A | 1 |
| Lauria, G | 1 |
| Piamarta, F | 1 |
| Fiumani, A | 1 |
| Agostoni, E | 1 |
| Yang, ZX | 1 |
| Xiong, H | 1 |
| Zhang, YH | 1 |
| Bao, XH | 1 |
| Jiang, YW | 1 |
| Chang, XZ | 1 |
| Qin, J | 1 |
| Lin, Q | 1 |
| Wu, XR | 1 |
| Rawoot, A | 1 |
| Renison, R | 1 |
| Badri, M | 1 |
| Sanders, D | 2 |
| Baron, J | 1 |
| Lin, H | 1 |
| Penumalli, V | 1 |
| van Besien, K | 1 |
| Sri-udomkajorn, S | 1 |
| Panichai, P | 1 |
| Liumsuwan, S | 1 |
| Scheer, BV | 1 |
| Valero-Burgos, E | 1 |
| Costa, R | 1 |
| Melbourne Chambers, R | 1 |
| Forrester, S | 1 |
| Gray, R | 1 |
| Tapper, J | 1 |
| Trotman, H | 1 |
| Bruce, BB | 1 |
| Stefanescu, AM | 1 |
| Ungureanu, E | 1 |
| Tugui, A | 1 |
| Gradinaru, SL | 1 |
| Hansen, P | 1 |
| Van Toorn, R | 1 |
| Lubbe, E | 1 |
| Janse van Rensburg, E | 1 |
| Wilmshurst, JM | 1 |
| Koul, R | 1 |
| Al Futaisi, A | 1 |
| Abdwani, R | 1 |
| Wang, YZ | 1 |
| Yan, M | 1 |
| Tian, FF | 1 |
| Zhang, JM | 1 |
| Liu, Q | 1 |
| Zhou, WB | 1 |
| Li, J | 1 |
| Alaama, T | 1 |
| Basharat, P | 1 |
| Nicolle, MW | 3 |
| Mosberg-Galili, R | 1 |
| Bisonni, A | 1 |
| Mastrorosa, A | 1 |
| Bartocccioni, E | 1 |
| McDermott, MP | 1 |
| Tawil, R | 1 |
| Werner, P | 1 |
| Kiechl, S | 1 |
| Thaler, C | 1 |
| Willeit, J | 1 |
| Poewe, W | 1 |
| Baldissera, I | 1 |
| Djelmis, J | 1 |
| Sostarko, M | 1 |
| Mayer, D | 1 |
| Ivanisevic, M | 1 |
| Katzberg, HD | 1 |
| Aziz, T | 1 |
| Gajdos, P | 3 |
| Chevret, S | 1 |
| Toyka, K | 1 |
| Latkany, R | 1 |
| Homel, P | 1 |
| Li, ZX | 1 |
| Tan, H | 1 |
| Xiong, XJ | 1 |
| Scoppetta, C | 4 |
| Onorati, P | 1 |
| Eusebi, F | 1 |
| Fini, M | 1 |
| Tonali, PA | 2 |
| Padua, L | 1 |
| Monaco, ML | 1 |
| Scuderi, F | 1 |
| Batocchi, AP | 4 |
| Marino, M | 1 |
| Kim, JH | 1 |
| Hwang, JM | 1 |
| Hwang, YS | 1 |
| Kim, KJ | 1 |
| Chae, J | 1 |
| MONHEIT, DB | 1 |
| KLEIN, JJ | 1 |
| GOTTLIEB, AJ | 1 |
| MONES, RJ | 1 |
| APPEL, SH | 1 |
| OSSERMAN, KE | 2 |
| WALTON, JN | 1 |
| MAEKELAE, TE | 1 |
| RUOSTEENOJA, R | 1 |
| WAGER, O | 1 |
| WALLGREN, GR | 1 |
| JOKINEN, EJ | 1 |
| Papapetropoulos, TH | 1 |
| Ellul, J | 1 |
| Tsibri, E | 1 |
| Wang, HS | 1 |
| Greenberg, SA | 1 |
| Monsul, NT | 1 |
| Knorr, AM | 1 |
| Lesser, RL | 1 |
| Zieliński, M | 2 |
| Kuzdzał, J | 1 |
| Staniec, B | 1 |
| Harazda, M | 1 |
| Nabiałek, T | 1 |
| Pankowski, J | 1 |
| Szlubowski, A | 1 |
| Medoń, J | 1 |
| Lafleur, L | 1 |
| Beaty, S | 1 |
| Colome-Grimmer, MI | 1 |
| LaForte, RA | 1 |
| Dotson, AD | 1 |
| Rowin, J | 1 |
| Meriggioli, MN | 1 |
| Tüzün, E | 1 |
| Leurgans, S | 1 |
| Christadoss, P | 1 |
| Schneider-Gold, C | 1 |
| Toyka, KV | 1 |
| Hohlfeld, RR | 1 |
| Fort, JM | 4 |
| Buera, M | 2 |
| Cervera, C | 1 |
| Tireli, H | 1 |
| Karlikaya, G | 1 |
| Tutkavul, K | 1 |
| Akpinar, A | 1 |
| Okay, T | 1 |
| Fattorossi, A | 2 |
| Battaglia, A | 2 |
| Buzzonetti, A | 2 |
| Ciaraffa, F | 1 |
| Scambia, G | 2 |
| Vernino, S | 1 |
| Salomao, DR | 1 |
| Habermann, TM | 1 |
| O'Neill, BP | 1 |
| Lin, PT | 1 |
| Martin, BA | 1 |
| Weinacker, AB | 1 |
| So, YT | 1 |
| Ying, G | 1 |
| Avni, I | 1 |
| Sharabi, Y | 1 |
| Sadeh, M | 1 |
| Buchman, AS | 1 |
| Aarli, JA | 1 |
| Phillips, LH | 1 |
| Kuzdzal, J | 1 |
| Kanzaki, M | 2 |
| Obara, T | 2 |
| Sasano, S | 2 |
| Onuki, T | 2 |
| Bae, JS | 1 |
| Go, SM | 1 |
| Kim, BJ | 1 |
| Goss, JM | 1 |
| Nord, KM | 1 |
| Olarte, MR | 1 |
| Grossman, ME | 1 |
| Fasano, A | 1 |
| Piano, C | 1 |
| Bentivoglio, AR | 1 |
| Díaz-Manera, J | 1 |
| Rojas-García, R | 1 |
| Gallardo, E | 1 |
| Juárez, C | 1 |
| Martínez-Domeño, A | 1 |
| Martínez-Ramírez, S | 1 |
| Dalmau, J | 1 |
| Blesa, R | 1 |
| Illa, I | 3 |
| Bhagavati, S | 1 |
| Maccabee, PJ | 1 |
| Chari, G | 1 |
| Kakoulidou, M | 1 |
| Pirskanen-Matell, R | 1 |
| Lefvert, AK | 2 |
| Minicuci, G | 1 |
| Riso, R | 1 |
| Peri, L | 1 |
| Gilbert, ME | 1 |
| De Sousa, EA | 1 |
| Savino, PJ | 2 |
| Chavis, PS | 1 |
| Stickler, DE | 1 |
| Walker, A | 1 |
| Roach, ES | 1 |
| Reffet, A | 1 |
| Oddes, B | 1 |
| Terrier, F | 1 |
| Chauveau, E | 1 |
| Casassus-Buihle, D | 1 |
| Fraudin, A | 1 |
| Wang, SH | 1 |
| Feng, J | 1 |
| Chan, JW | 1 |
| Hikawa, Y | 1 |
| Hart, IK | 1 |
| Shukla, SS | 1 |
| Siddiqi, ZA | 1 |
| De Baets, MH | 1 |
| Melms, A | 1 |
| Solomons, N | 1 |
| Richman, DP | 1 |
| Eden, RD | 1 |
| Gall, SA | 1 |
| Streib, EW | 2 |
| Rothner, AD | 1 |
| Bateman, BG | 1 |
| Nunley, WC | 1 |
| Kitchin, JD | 1 |
| Abramsky, O | 4 |
| Fiacchino, F | 2 |
| Crenna, P | 1 |
| Sghirlanzoni, A | 3 |
| Peluchetti, D | 2 |
| Allegranza, A | 1 |
| Seybold, ME | 2 |
| Fauci, AS | 1 |
| Wang, DC | 1 |
| Calabrese, LH | 1 |
| Bach, JF | 2 |
| Currie, T | 1 |
| Vidt, D | 1 |
| Clough, J | 1 |
| Krakauer, RS | 1 |
| Patzold, U | 1 |
| Kalies, I | 1 |
| Haas, J | 1 |
| Ginda, EM | 1 |
| Schumm, F | 2 |
| Fateh-Moghadam, A | 2 |
| Dichgans, J | 1 |
| Cornelio, F | 2 |
| Brinkmann, A | 1 |
| Berrih, S | 1 |
| Safar, D | 1 |
| Levasseur, P | 1 |
| Gaud, C | 1 |
| Coslett, HB | 1 |
| Johns, TR | 8 |
| Maddison, JE | 1 |
| Waelchli-Suter, CM | 1 |
| Johnson, RP | 1 |
| Witte, AS | 1 |
| Cornblath, DR | 1 |
| Parry, GJ | 1 |
| Lisak, RP | 1 |
| Schatz, NJ | 2 |
| Goodman, BW | 1 |
| Shepard, FA | 1 |
| Oosterhuis, HJ | 6 |
| Limburg, PC | 1 |
| Hummel-Tappel, E | 1 |
| The, TH | 1 |
| Tonali, P | 6 |
| David, P | 2 |
| Rodriguez, M | 2 |
| Gomez, MR | 2 |
| Howard, FM | 4 |
| Taylor, WF | 1 |
| Pugesgaard, T | 1 |
| Mertens, HG | 2 |
| Hertel, G | 2 |
| Reuther, P | 2 |
| Ricker, K | 1 |
| Dau, PC | 3 |
| Perlo, VP | 1 |
| Shahani, BT | 1 |
| Huggins, CE | 1 |
| Hunt, J | 1 |
| Kosinski, K | 1 |
| Potts, F | 1 |
| Bray, JJ | 1 |
| Drachman, DB | 2 |
| Heiser, JC | 1 |
| Rutherford, RB | 1 |
| Ringel, SP | 1 |
| Eppel, M | 1 |
| Valbonesi, M | 1 |
| Garelli, S | 1 |
| Zerbi, D | 1 |
| Forlani, G | 1 |
| Pelucchetti, D | 1 |
| Spalek, P | 1 |
| Lisý, L | 1 |
| Tindall, RS | 2 |
| Snead, OC | 1 |
| Benton, JW | 1 |
| Dwyer, D | 3 |
| Morley, BJ | 3 |
| Kemp, GE | 3 |
| Bradley, RJ | 3 |
| Oh, SJ | 3 |
| Perez, MC | 1 |
| Buot, WL | 1 |
| Mercado-Danguilan, C | 1 |
| Bagabaldo, ZG | 1 |
| Renales, LD | 1 |
| Cordess, C | 1 |
| Folstein, M | 1 |
| Drachman, D | 1 |
| Olanow, CW | 3 |
| Roses, AD | 2 |
| Fay, JW | 1 |
| Breton, L | 1 |
| Gosselin, Y | 1 |
| Couture, L | 1 |
| Taylor, F | 1 |
| Wechsler, AS | 2 |
| Clark, RE | 1 |
| Marbarger, JP | 1 |
| West, PN | 1 |
| Spratt, JA | 1 |
| Florence, JM | 1 |
| Roper, CL | 1 |
| Ferguson, TB | 1 |
| Weldon, CS | 1 |
| Ito, N | 1 |
| Cowan, J | 1 |
| Moenning, JE | 1 |
| Bussard, DA | 1 |
| De Assis, JL | 3 |
| Marchiori, PE | 4 |
| Scaff, M | 3 |
| Vargas, ME | 1 |
| Warren, FA | 1 |
| Benshushan, A | 1 |
| Rojansky, N | 1 |
| Weinstein, D | 1 |
| Bhalla, R | 1 |
| Swedler, WI | 1 |
| Lazarevic, MB | 1 |
| Ajmani, HS | 1 |
| Skosey, JL | 1 |
| Phillips, JT | 1 |
| Rollins, JA | 1 |
| Wells, L | 1 |
| Hall, K | 1 |
| Lopate, G | 1 |
| Pestronk, A | 1 |
| Xu, X | 1 |
| Kuks, JB | 2 |
| Blom, RJ | 1 |
| Westerterp-Maas, A | 1 |
| Bromberg, MB | 1 |
| Wald, JJ | 1 |
| Forshew, DA | 1 |
| Feldman, EL | 1 |
| Albers, JW | 1 |
| Kodama, K | 1 |
| Doi, O | 1 |
| Higashiyama, M | 1 |
| Yokouchi, H | 1 |
| Yasuda, T | 1 |
| Funai, H | 1 |
| Korn-Lubetzki, I | 1 |
| Virozov, Y | 1 |
| Klar, A | 1 |
| Morosetti, M | 1 |
| Meloni, C | 1 |
| Iani, C | 1 |
| Caramia, M | 1 |
| Galderisi, C | 1 |
| Palombo, G | 1 |
| Gallucci, MT | 1 |
| Bernardi, G | 1 |
| Casciani, CU | 1 |
| Marzo, ME | 1 |
| Pérez López-Fraile, I | 1 |
| Capablo, JL | 1 |
| Ara, JR | 1 |
| Usón, M | 1 |
| Strong, J | 1 |
| Zochodne, DW | 1 |
| Cherasse, A | 1 |
| Maillefert, JF | 1 |
| Henlin, JL | 1 |
| Chassard, D | 1 |
| Tavernier, C | 1 |
| Ataga, KI | 1 |
| Graham, ML | 1 |
| Evans, HN | 1 |
| Braeuning, P | 1 |
| Orringer, EP | 1 |
| Kuckelhaus, CS | 1 |
| Amaral, K | 1 |
| Mullaney, P | 1 |
| Vajsar, J | 1 |
| Smith, R | 1 |
| Buncic, JR | 1 |
| Leavitt, JA | 1 |
| Kornizky, Y | 1 |
| Heller, I | 1 |
| Isakov, A | 1 |
| Shapira, I | 1 |
| Topilsky, M | 1 |
| Pijnenborg, JM | 1 |
| Hansen, EC | 1 |
| Brölmann, HA | 1 |
| Oei, SG | 1 |
| Andriessen, P | 1 |
| Dellemijn, PL | 1 |
| Minisci, C | 1 |
| Di Schino, C | 1 |
| Leddy, JJ | 1 |
| Chutkow, JG | 1 |
| Sempowski, G | 1 |
| Thomasch, J | 1 |
| Gooding, M | 1 |
| Hale, L | 1 |
| Edwards, L | 1 |
| Massey, J | 1 |
| Douek, D | 1 |
| Koup, R | 1 |
| Haynes, B | 1 |
| Weizer, JS | 1 |
| Coats, DK | 1 |
| Abt, PL | 1 |
| Patel, HJ | 1 |
| Marsh, A | 1 |
| Schwartz, SI | 1 |
| Mowzoon, N | 1 |
| Sussman, A | 1 |
| Bradley, WG | 1 |
| Morita, MP | 1 |
| Gabbai, AA | 1 |
| Oliveira, AS | 1 |
| Penn, AS | 1 |
| LeePan, EB | 1 |
| Eastman, RW | 1 |
| Han, Z | 1 |
| Xu, W | 1 |
| Wei, Y | 1 |
| Lei, S | 1 |
| Espin, E | 1 |
| Popescu, I | 1 |
| Tomulescu, V | 1 |
| Ion, V | 1 |
| Tulbure, D | 1 |
| Pinching, AJ | 1 |
| Peters, DK | 1 |
| Robinson, G | 2 |
| Wilson, SG | 1 |
| Ward, CD | 1 |
| Crucitti, F | 1 |
| Vaccario, ML | 1 |
| Somer, H | 1 |
| Pirskanen, R | 1 |
| Wasastjerna, C | 1 |
| Konttinen, A | 1 |
| Mozai, T | 1 |
| Vijayan, N | 1 |
| Dreyfus, PM | 1 |
| Papazian, O | 1 |
| Brunner, NG | 4 |
| Berger, CL | 1 |
| Namba, T | 3 |
| Grob, D | 4 |
| Duane, DD | 1 |
| Lambert, EH | 1 |
| Daube, JR | 1 |
| Jerusalem, F | 1 |
| Vasilescu, C | 1 |
| Bucur, G | 1 |
| Petrovici, A | 1 |
| Florescu, A | 1 |
| Dawkins, RL | 1 |
| Stewart, PM | 1 |
| Lamang, M | 1 |
| Truniger, B | 1 |
| Harati, Y | 1 |
| Patten, BM | 6 |
| Winkler, LH | 1 |
| Winkler, GF | 1 |
| Wiebecke, D | 1 |
| Böske, A | 1 |
| Dobkin, BH | 1 |
| Sarnat, HB | 1 |
| McGarry, JD | 1 |
| Lewis, JE | 1 |
| Mendell, JR | 1 |
| Warmolts, JR | 4 |
| Bass, JC | 1 |
| Morgutti, M | 1 |
| Conti-Tronconi, BM | 1 |
| Clementi, F | 1 |
| Bolooki, H | 1 |
| Schwartzman, RJ | 2 |
| Galdi, AP | 1 |
| Matell, G | 1 |
| Osterman, PO | 1 |
| Vidal Secanell, JM | 1 |
| Maudes Rodríguez, A | 1 |
| Keesey, J | 2 |
| Shaikh, I | 1 |
| Wolfgram, F | 1 |
| Chao, LP | 1 |
| Engel, WK | 7 |
| Maize, JC | 1 |
| Dobson, RL | 1 |
| Provost, TT | 1 |
| Mann, JD | 3 |
| Campa, JF | 4 |
| Lindstrom, JM | 1 |
| Cassel, CK | 1 |
| Denys, EH | 1 |
| Shev, EE | 1 |
| Spitler, LE | 1 |
| Newball, HH | 2 |
| Brahim, SA | 1 |
| Muller, WH | 2 |
| Fischer, KC | 2 |
| Melamed, E | 1 |
| Reches, A | 1 |
| Silberberg, R | 1 |
| Soffer, D | 1 |
| Lamartine de Assis, J | 1 |
| Osher, RH | 1 |
| Smith, JL | 1 |
| Aharonov, A | 2 |
| Teitelbaum, D | 1 |
| Fuchs, S | 2 |
| Strother, CM | 1 |
| Goldman, AJ | 2 |
| Hermann, C | 1 |
| Mulder, DG | 2 |
| Brown, WJ | 2 |
| Herrmann, C | 1 |
| Keesey, JC | 1 |
| Webb, C | 1 |
| Herishanu, Y | 1 |
| Feldman, S | 1 |
| Ashizawa, T | 1 |
| Ruan, KH | 1 |
| Jinnai, K | 1 |
| Atassi, MZ | 1 |
| Xu, JZ | 1 |
| Palmisani, MT | 2 |
| Lo Monaco, M | 2 |
| Badurska, B | 1 |
| Ryniewicz, B | 1 |
| Strugalska, H | 1 |
| Carr, SR | 1 |
| Gilchrist, JM | 1 |
| Abuelo, DN | 1 |
| Clark, D | 1 |
| Cosi, V | 2 |
| Citterio, A | 1 |
| Lombardi, M | 2 |
| Piccolo, G | 2 |
| Romani, A | 1 |
| Erbetta, A | 1 |
| Bove, R | 1 |
| Filippini, C | 1 |
| Millefiorini, M | 1 |
| Miano, MA | 1 |
| Bosley, TM | 1 |
| Heiman-Patterson, TD | 1 |
| Reed, J | 1 |
| Sergott, RC | 1 |
| Müller, KM | 1 |
| Nykyri, E | 1 |
| Andersson, LC | 1 |
| Bartoccioni, M | 1 |
| Hood, LJ | 1 |
| Bartges, JW | 1 |
| Klausner, JS | 1 |
| Bostwick, EF | 1 |
| Hakala, JE | 1 |
| Lennon, VA | 1 |
| Nasca, TJ | 2 |
| Muder, RR | 2 |
| Thomas, DB | 1 |
| Schrecker, JC | 1 |
| Ruben, FL | 1 |
| Rodgin, SG | 1 |
| Pradas, J | 2 |
| Koopman, WJ | 1 |
| Sandmann, MC | 1 |
| Gorz, AM | 1 |
| Gracia, CM | 1 |
| Batista, RJ | 1 |
| Seixas, RR | 1 |
| Bittencourt, PR | 1 |
| Murray, KB | 1 |
| Taylor, R | 2 |
| DiCostanzo, DP | 2 |
| Sharma, K | 2 |
| Fries, T | 2 |
| Roberts, J | 2 |
| Atkinson, K | 1 |
| Bryant, D | 1 |
| Delprado, W | 1 |
| Biggs, J | 1 |
| Aguiar, MF | 1 |
| Barbosa, H | 1 |
| Vilela, SS | 1 |
| Henze, T | 1 |
| Dooley, JM | 1 |
| Writer, H | 1 |
| Gibson, EJ | 1 |
| MacSween, J | 1 |
| Fève, JR | 1 |
| Johnson, RB | 1 |
| Kominos, SD | 1 |
| Bixenman, WW | 1 |
| Buchsbaum, HW | 1 |
| Arsura, EL | 2 |
| Bick, A | 2 |
| Valli, G | 1 |
| Jann, S | 1 |
| Premoselli, S | 1 |
| Scarlato, G | 1 |
| Sirotkin-Roses, M | 1 |
| Stajich, J | 1 |
| Jankovic, J | 1 |
| Hinman, CL | 1 |
| Ernstoff, RM | 1 |
| Montgomery, IN | 2 |
| Hudson, RA | 1 |
| Rauch, HC | 2 |
| Hoogenraad, TU | 1 |
| Gmelig Meyling, FH | 1 |
| Scherpbier, HJ | 1 |
| Miller, RG | 1 |
| Milner-Brown, HS | 1 |
| Mirka, A | 1 |
| Vázquez, J | 1 |
| Codina, M | 1 |
| Verma, AK | 1 |
| Behari, M | 1 |
| Ahuja, GK | 1 |
| Zambon, AA | 2 |
| Gutmann, L | 1 |
| Warden, HE | 1 |
| Wertheimer, RI | 1 |
| Riggs, JE | 1 |
| Bargman, HB | 1 |
| Fefferman, I | 1 |
| Sellman, MS | 2 |
| Mayer, RF | 2 |
| Huber, A | 1 |
| Curi, N | 1 |
| Filomeno, LT | 1 |
| Fornasari, PM | 1 |
| Riva, G | 1 |
| Brentani, MM | 1 |
| Martins, VR | 1 |
| Kaplan, J | 1 |
| Whitaker, JN | 1 |
| Dalby, A | 1 |
| Kjaer, M | 2 |
| de Fine Olivarius, B | 1 |
| Jenkins, RB | 1 |
| Clarke, SW | 1 |
| Kendall, MJ | 1 |
| Pirofsky, B | 1 |
| Reid, RR | 1 |
| Ramirez-Mateos, JC | 1 |
| Bardana, EJ | 1 |
| August, A | 1 |
| MacKechnie, HL | 1 |
| Squires, AH | 1 |
| Platts, M | 1 |
| Pruzanski, W | 1 |
| Aita, JF | 1 |
| Snyder, DH | 1 |
| Reichl, W | 1 |
| Peck, SM | 1 |
| Weiner, LB | 1 |
| Lefkovits, A | 1 |
| Osserman, RS | 1 |
| Miller, TN | 1 |
| Bammer, HG | 1 |
| Cohen, JS | 1 |
| Selecky, PA | 1 |
| Ziment, I | 1 |
| Oliver, KL | 2 |
| Festoff, BW | 1 |
| Swerdlow, ML | 1 |
| Thompson, MD | 1 |
| Walsh, JC | 1 |
| Cendrowski, W | 1 |
| Riekkinen, PJ | 1 |
| Rinne, UK | 1 |
| Buscaino, GA | 1 |
| Eisen, AA | 1 |
| Norris, JW | 1 |
| Pinelli, P | 1 |
| Chriss, JW | 1 |
| Susac, JO | 1 |
| Garcia-Mullin, R | 1 |
| Glaser, JS | 1 |
| McQuillen, MP | 1 |
| Tan, RS | 1 |
| Schwartzmann, RJ | 1 |
| Haas, DC | 1 |
| Arnason, BG | 1 |
| Doll, R | 1 |
| Kinlen, L | 1 |
| Jablonska, S | 1 |
| Chorzelski, T | 1 |
| Lebioda, J | 1 |
| MacGregor, GA | 2 |
| de Fine Olivarius, AB | 1 |
| Thage, O | 1 |
| Böttcher, D | 1 |
| Maas, D | 1 |
| Wendt, F | 1 |
| Schubothe, H | 1 |
| Crowley, WJ | 1 |
| Miller, JQ | 1 |
| Rüster, M | 1 |
| Dietel, K | 1 |
| Defféminis Rospide, HA | 1 |
| Scarabino, R | 1 |
| Firpo, E | 1 |
| Riehl, JL | 1 |
| Hanley, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisone[NCT00294658] | Phase 3 | 126 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, 36-Week Trial to Assess the Efficacy and Safety of Adjunct Mycophenolate Mofetil (MMF) to Maintain or Improve Symptom Control With Reduced Corticosteroid in Subjects[NCT00683969] | Phase 3 | 136 participants (Anticipated) | Interventional | 2004-08-31 | Completed | ||
| Influence of Minimally Invasive Thymectomy on the Subsequent Clinical Course of Myasthenia Gravis[NCT04158661] | 248 participants (Actual) | Observational | 2020-04-20 | Active, not recruiting | |||
| Interest of Plasma Exchange in Patients With Anti-interferon Type 1 Autoantibodies With Severe COVID-19 -[NCT05182515] | Phase 3 | 50 participants (Anticipated) | Interventional | 2021-12-22 | Recruiting | ||
| Phase 1-2 Pilot Study of Rituximab (Rituxan) in Refractory Myasthenia Gravis.[NCT00619671] | Phase 1/Phase 2 | 10 participants (Anticipated) | Interventional | 2004-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00294658)
Timeframe: baseline to 3 years
| Intervention | participants (Number) |
|---|---|
| Thymectomy Plus Prednisone | 11 |
| Prednisone Alone | 28 |
Number of patients with MG exacerbation: Thymectomy plus prednisone=6 (out of 66); Prednisone alone=17 (out of 60) (NCT00294658)
Timeframe: baseline to 2 years
| Intervention | days (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 5.5 |
| Prednisone Alone | 26.4 |
Number of patients with MG exacerbation: Thymectomy plus prednisone=6 (out of 66); Prednisone alone=22 (out of 60) (NCT00294658)
Timeframe: baseline to 3 years
| Intervention | days (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 8.7 |
| Prednisone Alone | 22.5 |
Number who had hospitalization: Thymectomy plus prednisone n=15 (out of 66); Prednisone alone n=31 (out of 60) (NCT00294658)
Timeframe: baseline to 3 years
| Intervention | days (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 8.4 |
| Prednisone Alone | 19.2 |
(NCT00294658)
Timeframe: baseline to 3 years
| Intervention | participants (Number) |
|---|---|
| Thymectomy Plus Prednisone | 11 |
| Prednisone Alone | 23 |
Number of participant who experienced at least one serious adverse events over 3 years: Thymectomy plus prednisone n=25 (out of 66); Prednisone alone n=33 (out of 60) (NCT00294658)
Timeframe: baseline to 3 years
| Intervention | participants (Number) |
|---|---|
| Thymectomy Plus Prednisone | 25 |
| Prednisone Alone | 33 |
Number of participant who experienced at least one serious adverse events over 3 years: Thymectomy plus prednisone n=25 (out of 66); Prednisone alone n=33 (out of 60) (NCT00294658)
Timeframe: baseline to 3 years
| Intervention | events (Number) |
|---|---|
| Thymectomy Plus Prednisone | 48 |
| Prednisone Alone | 93 |
For each participant who took azathioprine, we penalized them by taking the maximum dose of prednisone before azathioprine was added. We then applied the same method to compute the time-weighted alternative day prednisone dose from baseline, month 3, 4, 6 and every 3 months through 36 months. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months
| Intervention | mg (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 34.4 |
| Prednisone Alone | 64.4 |
For each participant who took azathioprine, we penalized them by taking the prednisone dose at the time azathioprine commenced. We then applied the same method to compute the time-weighted alternative day prednisone dose from baseline, month 3, 4, 6 and every 3 months through 36 months. (NCT00294658)
Timeframe: baseline, month 1 , 2 , 3, 4, 6 and every 3 months through 36 months
| Intervention | mg (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 33.3 |
| Prednisone Alone | 57.9 |
(NCT00294658)
Timeframe: baseline to 3 years
| Intervention | participants (Number) |
|---|---|
| Thymectomy Plus Prednisone | 10 |
| Prednisone Alone | 9 |
Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period. (NCT00294658)
Timeframe: baseline, month 1 , 2 , 3, 4, 6 and every 3 months through 36 months
| Intervention | mg (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 32 |
| Prednisone Alone | 54 |
MG Activity of Daily Living total scores range from 0 to 24, with the lower scores indicating better daily living quality of life. (NCT00294658)
Timeframe: baseline, month 4, 6 and every 3 months through 36 months
| Intervention | units on a scale (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 2.24 |
| Prednisone Alone | 3.41 |
Physicians reported prescribed alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prescribed prednisone dosages had been weighted over the days of reporting period. (NCT00294658)
Timeframe: baseline-day 20, month 1,2, 3, 4, 6 and every 3 months through 36 months
| Intervention | mg (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 34.3 |
| Prednisone Alone | 55.6 |
Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. The time weighted average is a calculation that provides an integrated measure of the outcome over the time of followup. The denominator that was used to compute the time-weighted average for the Quantitative Myasthenia Gravis (QMG) score and the prednisone dose was the number of days from randomization to the last visit. Computations used the trapezoidal method where in the QMG score is multiplied by the number of days at this level from one visit to the next and added up over the entire followup experience and divided by the total number of days from randomization. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months
| Intervention | units on a scale (Mean) |
|---|---|
| Thymectomy Plus Prednisone | 6.15 |
| Prednisone Alone | 8.99 |
(NCT00294658)
Timeframe: baseline to 3 years
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Life-threatening | Disability or incapacity | Medical or surgical intervention | Death | Complication due to thytmectomy | Hospitalization | |
| Prednisone Alone | 7 | 2 | 5 | 1 | 0 | 31 |
| Thymectomy Plus Prednisone | 1 | 8 | 9 | 0 | 1 | 15 |
(NCT00294658)
Timeframe: baseline to 2 years and baseline to 3 years
| Intervention | participants (Number) | |
|---|---|---|
| Months 0-24 | Months 0-36 | |
| Prednisone Alone | 17 | 22 |
| Thymectomy Plus Prednisone | 6 | 6 |
Number of participants who were in minimal manifestation status at month 12, 24 and 36. (NCT00294658)
Timeframe: Month 12, 24 and 36
| Intervention | participants (Number) | ||
|---|---|---|---|
| Month 12 | Month 24 | Month 36 | |
| Prednisone Alone | 20 | 20 | 24 |
| Thymectomy Plus Prednisone | 41 | 39 | 39 |
Number who had hospitalization: Thymectomy plus prednisone n=15 (out of 66); Prednisone alone n=31 (out of 60) (NCT00294658)
Timeframe: baseline to 3 years
| Intervention | events (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Gastrointestinal disorder | Hepatobiliary disorder | Infection or infestation | Injury, poisoning, or procedure complication | Metabolism or nutrition disorder | Nervous system disorder | Respiratory, thoracic, or mediastinal disorder | Surgical or medical procedure | Vascular disorder | |
| Prednisone Alone | 2 | 1 | 7 | 0 | 0 | 22 | 2 | 7 | 1 |
| Thymectomy Plus Prednisone | 2 | 0 | 4 | 2 | 1 | 8 | 1 | 0 | 0 |
Range from 0 to 100, the higher the mental component value, the better the mental health. (NCT00294658)
Timeframe: Month 0, Month 12, Month 24 and Month 36
| Intervention | units on a scale (Median) | |||
|---|---|---|---|---|
| Month 0 | Month 12 | Month 24 | Month 36 | |
| Prednisone Alone | 46.2 | 41.7 | 46.7 | 48.2 |
| Thymectomy Plus Prednisone | 49.1 | 39.1 | 49.9 | 51.7 |
Range from 0 to 100, the higher the physical component value, the better the mental health. (NCT00294658)
Timeframe: Month 0, Month 12, Month 24 and Month 36
| Intervention | units on a scale (Median) | |||
|---|---|---|---|---|
| Month 0 | Month 12 | Month 24 | Month 36 | |
| Prednisone Alone | 37.9 | 44.4 | 43.0 | 44.2 |
| Thymectomy Plus Prednisone | 41.4 | 48.4 | 50.3 | 48.2 |
Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months
| Intervention | mg (Mean) | |
|---|---|---|
| Not prednisone naïve | Prednisone naïve | |
| Prednisone Alone | 56 | 45 |
| Thymectomy Plus Prednisone | 35 | 25 |
Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months
| Intervention | mg (Mean) | |
|---|---|---|
| Female | Male | |
| Prednisone Alone | 54 | 55 |
| Thymectomy Plus Prednisone | 33 | 31 |
Participants reported alternate-day prednisone dose (mg) intake from baseline through withdrawn or completed 3 years follow up. The prednisone dosages had been weighted over the days of reporting period. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months
| Intervention | mg (Mean) | |
|---|---|---|
| Age (Years) at Disease Onset < 40 | Age (Years) at Disease Onset ≥ 40 | |
| Prednisone Alone | 55 | 49 |
| Thymectomy Plus Prednisone | 35 | 27 |
Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Age (years) at Disease Onset < 40 | Age (years) at Disease Onset ≥ 40 | |
| Prednisone Alone | 9.60 | 7.85 |
| Thymectomy Plus Prednisone | 6.50 | 5.33 |
Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Not prednisone naïve | Prednisone naïve | |
| Prednisone Alone | 9.10 | 8.84 |
| Thymectomy Plus Prednisone | 6.30 | 5.66 |
Myasthenia Gravis (QMG) test. QMG total scores range from 0 to 39 for a given visit, with higher scores indicating more severe disease. (NCT00294658)
Timeframe: baseline, month 3, 4, 6 and every 3 months through 36 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Female | Male | |
| Prednisone Alone | 9.73 | 7.45 |
| Thymectomy Plus Prednisone | 6.47 | 5.23 |
MG Activity of Daily Living total scores range from 0 to 24 by visit, with the lower scores indicating better daily living quality of life. (NCT00294658)
Timeframe: Month 12, 24, and 36
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Month 12 | Month 24 | Month 36 | |
| Prednisone Alone | 3.33 | 3.11 | 2.69 |
| Thymectomy Plus Prednisone | 1.92 | 2.02 | 2.14 |
Treatment associated complications measured complications occurred by myasthenia gravis patients. Report number of participant with at least one complications by each visit. (NCT00294658)
Timeframe: Month 0, 1, 2, 3, 4 then every 3 months through Month 36
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Month 0 | Month 1 | Month 2 | Month 3 | Month 4 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Mpnth 24 | Mpnth 27 | Month 30 | Month 33 | Month 36 | |
| Prednisone Alone | 17 | 15 | 20 | 16 | 23 | 22 | 26 | 28 | 24 | 24 | 20 | 23 | 17 | 19 | 23 | 23 |
| Thymectomy Plus Prednisone | 22 | 15 | 22 | 21 | 23 | 21 | 37 | 35 | 29 | 28 | 22 | 28 | 25 | 23 | 24 | 23 |
Treatment associated symptoms measured myasthenia gravis symptoms such as back pain and/or bruises. Report number of participant with at least one treatment associated symptoms by each visit. (NCT00294658)
Timeframe: Month 0, 1, 2, 3, 4 then every 3 months through Month 36
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Month 0 | Month 1 | Month 2 | Month 3 | Month 4 | Month 6 | Month 9 | Month 12 | Month 15 | Month 18 | Month 21 | Mpnth 24 | Mpnth 27 | Month 30 | Month 33 | Month 36 | |
| Prednisone Alone | 53 | 52 | 53 | 54 | 54 | 53 | 50 | 52 | 51 | 51 | 50 | 51 | 50 | 50 | 48 | 47 |
| Thymectomy Plus Prednisone | 63 | 55 | 61 | 60 | 59 | 60 | 59 | 56 | 56 | 52 | 52 | 52 | 50 | 49 | 51 | 49 |
28 reviews available for prednisone and Anti-MuSK Myasthenia Gravis
| Article | Year |
|---|---|
Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Chemoradiotherapy; Colitis; Humans; Immune Checkpoint Inhib | 2021 |
Diagnosis and Management of Myasthenia Gravis.
Topics: Adult; Autoantibodies; Humans; Immunosuppressive Agents; Multicenter Studies as Topic; Myasthenia Gr | 2022 |
Methotrexate in generalized myasthenia gravis: a systematic review.
Topics: Azathioprine; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Met | 2023 |
Practice advisory: Thymectomy for myasthenia gravis (practice parameter update): Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Topics: Autoantibodies; Combined Modality Therapy; Glucocorticoids; Humans; Minimally Invasive Surgical Proc | 2020 |
Effectiveness and safety of thymectomy plus prednisone compares with prednisone monotherapy for the treatment of non-thymomatous Myasthenia Gravis: Protocol for a systematic review.
Topics: Anti-Inflammatory Agents; Combined Modality Therapy; Humans; Myasthenia Gravis; Prednisone; Thymecto | 2020 |
Dysphagia and Dysphonia, a Pairing of Symptoms Caused by an Unusual Pair of Diseases: Castleman's Disease and Myasthenia Gravis.
Topics: Adolescent; Castleman Disease; Cholinesterase Inhibitors; Deglutition Disorders; Dysphonia; Female; | 2021 |
[Course and treatment of myasthenia gravis during pregnancy].
Topics: Adult; Anti-Inflammatory Agents; Arthrogryposis; Autoantibodies; Breast Feeding; Cesarean Section; C | 2010 |
Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature.
Topics: 2-Chloroadenosine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2012 |
Myasthenia gravis in Jamaican children: a 12-year institutional review.
Topics: Adolescent; Child; Child, Preschool; Cholinesterase Inhibitors; Female; Glucocorticoids; Hospitals, | 2012 |
Myasthenia gravis in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Diagnosis, Differential; Early Diagnosis; Female; Humans; Isra | 2013 |
Myasthenia gravis in pregnancy: report on 69 cases.
Topics: Adult; Birth Weight; Breast Feeding; Cesarean Section; Comorbidity; Female; Humans; Hyperbilirubinem | 2002 |
Plasma exchange for myasthenia gravis.
Topics: Combined Modality Therapy; Glucocorticoids; Humans; Myasthenia Gravis; Plasma Exchange; Prednisone; | 2002 |
SOME DISEASES OF MUSCLE.
Topics: Betamethasone; Cushing Syndrome; Dexamethasone; Diagnosis; Humans; Muscular Diseases; Muscular Dystr | 1964 |
Corticosteroids for myasthenia gravis.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Azathioprine; Glucocorticoids; Humans; Immunog | 2005 |
Ocular Myasthenia Gravis treatment: the case against prednisone therapy and thymectomy.
Topics: Combined Modality Therapy; Eye Diseases; Humans; Immunosuppressive Agents; Myasthenia Gravis; Predni | 2007 |
Immunosuppressive or surgical treatment for ocular Myasthenia Gravis.
Topics: Combined Modality Therapy; Disease Progression; Eye Diseases; Humans; Immunosuppressive Agents; Myas | 2007 |
Myasthenia gravis and acetylcholine receptor: autoimmunity and steroid effects.
Topics: Adrenal Cortex Hormones; Animals; Autoantibodies; Autoimmune Diseases; Disease Models, Animal; Human | 1980 |
Myasthenia gravis. A clinical and basic science review.
Topics: Adrenal Cortex Hormones; Adult; Animals; Autoantibodies; Child; Disease Models, Animal; Electromyogr | 1983 |
Myasthenia gravis and preeclampsia.
Topics: Adult; Dyspnea; Female; Humans; Myasthenia Gravis; Pre-Eclampsia; Prednisone; Pregnancy | 1994 |
Autoimmune myasthenia gravis.
Topics: Adult; Age Factors; Antibody Formation; Autoimmune Diseases; Cyclosporine; Diagnosis, Differential; | 1993 |
[Myasthenia gravis and visceral lupus erythematosus].
Topics: Acetylcholine; Adult; Antibodies, Antinuclear; Antigen-Antibody Complex; Azathioprine; Cell Membrane | 1979 |
Studies on the ability of acetylcholine receptors to bind alpha-bungarotoxin after exposure to myasthenic serum.
Topics: Acetylcholine; Animals; Binding Sites; Bungarotoxins; Curare; Diaphragm; Hot Temperature; Humans; Mi | 1976 |
Myasthenia gravis, corticosteroids, anticholinesterases.
Topics: Adrenal Cortex Hormones; Aged; B-Lymphocytes; Cholinesterase Inhibitors; Drug Administration Schedul | 1976 |
Metastasizing thymoma and myasthenia gravis. Favorable response to glucocorticoids after failed chemotherapy and radiation therapy.
Topics: Drug Administration Schedule; Female; Humans; Middle Aged; Myasthenia Gravis; Prednisone; Pyridostig | 1990 |
[Familial myasthenia gravis: a case report in identical twins].
Topics: Adult; Autoantibodies; Diseases in Twins; Female; HLA-A Antigens; Homozygote; Humans; Infant; Myasth | 1989 |
Myasthenia gravis.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Autonomic Agents; Electromyo | 1974 |
Immunosuppressive therapy in neurological diseases.
Topics: Adrenocorticotropic Hormone; Azathioprine; Central Nervous System Diseases; Cyclophosphamide; Cytara | 1974 |
Adrenal steroid therapy in neurological disease. Part I.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Animals; Arteritis; Arthritis, Rheumatoid; Col | 1969 |
30 trials available for prednisone and Anti-MuSK Myasthenia Gravis
| Article | Year |
|---|---|
A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis.
Topics: Area Under Curve; Humans; Methotrexate; Myasthenia Gravis; Prednisone; Prospective Studies | 2022 |
Serum metabolomics of treatment response in myasthenia gravis.
Topics: Activities of Daily Living; Combined Modality Therapy; Glucocorticoids; Humans; Myasthenia Gravis; P | 2023 |
Minimal manifestation status and prednisone withdrawal in the MGTX trial.
Topics: Adolescent; Adult; Animals; Combined Modality Therapy; Female; Humans; Immunosuppressive Agents; Mal | 2020 |
Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Immunoglobulins, Intravenous; Male; Middle Aged; Mya | 2020 |
Optimal timing of thymectomy in nonthymomatous myasthenia gravis patients in China: A prospective study.
Topics: Adolescent; Adult; China; Clinical Protocols; Combined Modality Therapy; Female; Humans; Immunosuppr | 2018 |
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.
Topics: Adult; Female; Humans; Longitudinal Studies; Male; Myasthenia Gravis; Prednisone; Thymectomy; Treatm | 2019 |
Serum metabolomic response of myasthenia gravis patients to chronic prednisone treatment.
Topics: Adult; Female; Humans; Lipid Metabolism; Male; Metabolome; Metabolomics; Myasthenia Gravis; Neuromus | 2014 |
A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Autoantibodies; Canada; Double-Blind Method; Femal | 2016 |
Randomized Trial of Thymectomy in Myasthenia Gravis.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Female; Glucocorticoids; Hospitalization; Humans | 2016 |
Randomized Trial of Thymectomy in Myasthenia Gravis.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Female; Glucocorticoids; Hospitalization; Humans | 2016 |
Randomized Trial of Thymectomy in Myasthenia Gravis.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Female; Glucocorticoids; Hospitalization; Humans | 2016 |
Randomized Trial of Thymectomy in Myasthenia Gravis.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Female; Glucocorticoids; Hospitalization; Humans | 2016 |
Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone.
Topics: Adult; Humans; Middle Aged; Myasthenia Gravis; Prednisone; Thymectomy; Time Factors | 2008 |
A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis.
Topics: Adult; Azathioprine; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Myas | 2011 |
Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial.
Topics: Cholinesterase Inhibitors; Double-Blind Method; Eye Diseases; Humans; Myasthenia Gravis; Placebos; P | 2012 |
[Clinical effect of Tripterygiitotorum combined with prednisone and its effect on serum IL-6 level in treating patients with myasthenia gravis].
Topics: Adolescent; Adult; B-Lymphocyte Subsets; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; G | 2002 |
Development of generalized myasthenia gravis in patients with ocular myasthenia gravis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Disease Progression; Eye Disea | 2003 |
Etanercept treatment in corticosteroid-dependent myasthenia gravis.
Topics: Adult; Autoantibodies; Drug Administration Schedule; Etanercept; Female; Humans; Immunoglobulin G; I | 2004 |
Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Ataxia; Autoantibodies; Cyclos | 2005 |
Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis.
Topics: Adolescent; Adult; Aged; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Middle Age | 2006 |
Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Chemotherapy, Adjuvant; Combined Modality Therapy | 2007 |
[International project--MGTX study].
Topics: Glucocorticoids; Humans; International Cooperation; Myasthenia Gravis; Prednisone; Single-Blind Meth | 2007 |
[Electroacupuncture warming therapy combined with western medicine for treatment of myasthenia gravis and effect on IL-4 level in the patients].
Topics: Acupuncture Points; Adult; Combined Modality Therapy; Electroacupuncture; Female; Humans; Interleuki | 2007 |
Mycophenolate mofetil for ocular myasthenia.
Topics: Adult; Autoantibodies; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Immu | 2008 |
An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.
Topics: Female; Humans; Immunosuppressive Agents; International Cooperation; Male; Middle Aged; Myasthenia G | 2008 |
A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis.
Topics: Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; IMP Dehydr | 2008 |
A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group.
Topics: Adult; Azathioprine; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisone; Treatment Fai | 1993 |
A clinical therapeutic trial of cyclosporine in myasthenia gravis.
Topics: Adult; Aged; Autoantibodies; Cyclosporine; Double-Blind Method; Female; Humans; Male; Middle Aged; M | 1993 |
Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis.
Topics: Adult; Aged; Azathioprine; Cross-Over Studies; Female; Humans; Immunosuppressive Agents; Male; Middl | 1997 |
Plasmapheresis in severe forms of myasthenia gravis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Combined Modality Therapy; | 1998 |
Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Chronic Disease; Drug Therapy, Combination | 2001 |
Alternate-day prednisone: preliminary report of a double-blind controlled study.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Clinical Trials as Topic; Drug Administration Schedule; El | 1976 |
Results of an open trial of cyclosporine in a group of steroido-dependent myasthenic subjects.
Topics: Adolescent; Adult; Autoantibodies; Cyclosporins; Female; Humans; Male; Middle Aged; Myasthenia Gravi | 1990 |
336 other studies available for prednisone and Anti-MuSK Myasthenia Gravis
| Article | Year |
|---|---|
Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis.
Topics: Adrenal Cortex Hormones; Adult; Affect; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; | 2021 |
Methotrexate as a Steroid-Sparing Agent in Myasthenia Gravis: A Preliminary Retrospective Study.
Topics: Azathioprine; Humans; Immunosuppressive Agents; Methotrexate; Myasthenia Gravis; Prednisone; Retrosp | 2021 |
Antibodies to Full-Length Agrin Protein in Chinese Patients With Myasthenia Gravis.
Topics: Age of Onset; Aged; Agrin; Autoantibodies; Autoantigens; China; Cholinesterase Inhibitors; Female; G | 2021 |
Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.
Topics: Humans; Interleukin-2; Myasthenia Gravis; Prednisolone; Prednisone; Quality of Life; Tacrolimus; Tra | 2022 |
A single low-dose rituximab infusion in severe chronic refractory myasthenia gravis in resource-limited settings.
Topics: Autoantibodies; Graft vs Host Disease; Humans; Immunologic Factors; Myasthenia Gravis; Prednisone; R | 2022 |
Effect of treatment with Fufang Huangqi decoction on dose reductions and discontinuation of pyridostigmine bromide tablets, prednisone, and tacrolimus in patients with type I or II myasthenia gravis.
Topics: Drug Tapering; Drugs, Chinese Herbal; Hormones; Humans; Myasthenia Gravis; Prednisone; Pyridostigmin | 2022 |
Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.
Topics: Adolescent; Adult; Disease Progression; Humans; Male; Myasthenia Gravis; Nomograms; Prednisone; Retr | 2023 |
Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.
Topics: Adolescent; Adult; Disease Progression; Humans; Male; Myasthenia Gravis; Nomograms; Prednisone; Retr | 2023 |
Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.
Topics: Adolescent; Adult; Disease Progression; Humans; Male; Myasthenia Gravis; Nomograms; Prednisone; Retr | 2023 |
Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.
Topics: Adolescent; Adult; Disease Progression; Humans; Male; Myasthenia Gravis; Nomograms; Prednisone; Retr | 2023 |
A series of patients with refractory myasthenia gravis.
Topics: Female; Humans; Immunosuppressive Agents; Middle Aged; Myasthenia Gravis; Neoplasm Recurrence, Local | 2023 |
Effects of Qishen Dihuang Granules on Intestinal Microbiota in Experimental Autoimmune Myasthenia Gravis Model Rats.
Topics: Animals; Female; Gastrointestinal Microbiome; Lactobacillus; Myasthenia Gravis; Prednisone; Rats; Ra | 2023 |
Clinical Features, Treatment, and Prognostic Factors of Childhood-Onset Myasthenia Gravis in a Large Chinese Cohort.
Topics: Adolescent; East Asian People; Humans; Immunosuppressive Agents; Myasthenia Gravis; Prednisone; Prog | 2023 |
Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis.
Topics: Activities of Daily Living; Adolescent; Child; Child, Preschool; Humans; Micropeptides; Myasthenia G | 2023 |
Diplopia in a patient presenting with "blurred vision": a case report.
Topics: Diplopia; Female; Humans; Muscle Weakness; Myasthenia Gravis; Prednisone; Pyridostigmine Bromide; Vi | 2023 |
[Clinical effect of different immunosuppressive treatment regimens in children with ocular myasthenia gravis: a retrospective analysis].
Topics: Activities of Daily Living; Child; Glucocorticoids; Humans; Immunosuppressive Agents; Myasthenia Gra | 2023 |
Factors associated with acute exacerbations of myasthenia gravis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Disease P | 2019 |
Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis.
Topics: Adult; Age of Onset; Aged; Blepharoptosis; Cholinesterase Inhibitors; Cohort Studies; Deglutition Di | 2019 |
Mitral Valve Replacement with Thymectomy in a Patient with Ocular Myasthenia Gravis: Case Report.
Topics: Adult; Anesthetics, Combined; Anti-Inflammatory Agents; Drug Interactions; Female; Fentanyl; Heart V | 2019 |
Response to treatment in pediatric ocular myasthenia gravis.
Topics: Adolescent; Age of Onset; Anti-Inflammatory Agents; Child; Child, Preschool; Disease Progression; Fe | 2020 |
[Thymectomy in thymomatous and non-thymomatous myasthenia gravis: analysis of a cohort of 46 patients].
Topics: Acetylcholine; Adolescent; Adult; Aged; Autoantibodies; Autoimmune Diseases; Combined Modality Thera | 2020 |
miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Autoimmunity; B-Lymphocytes; Cells, Cultured; Child; Fem | 2020 |
Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study.
Topics: Activities of Daily Living; Combined Modality Therapy; Glucocorticoids; Humans; Myasthenia Gravis; O | 2020 |
ATM mutation in a patient with thymoma-associated myasthenia gravis.
Topics: Ataxia Telangiectasia Mutated Proteins; Breast Neoplasms; Carcinoma, Ductal, Breast; Cholinesterase | 2020 |
COVID-19 and generalized Myasthenia Gravis exacerbation: A case report.
Topics: Adult; Betacoronavirus; Cholinesterase Inhibitors; Coronavirus Infections; COVID-19; Disease Progres | 2020 |
Effect of Initial Prednisone Dosing on Ocular Myasthenia Gravis Control.
Topics: Blepharoptosis; Humans; Myasthenia Gravis; Prednisone; Retrospective Studies; Treatment Outcome | 2021 |
Myasthenia Gravis Associated With Programmed Death-1 (PD-1) Receptor Inhibitor Pembrolizumab: A 40-day Case Report.
Topics: Aged; Antibodies, Monoclonal, Humanized; Humans; Male; Myasthenia Gravis; Prednisone; Programmed Cel | 2021 |
Late-onset double-seronegative myasthenia gravis syndrome and myasthenic crisis due to nivolumab use for Hodgkin's lymphoma.
Topics: Dysarthria; Female; Hodgkin Disease; Humans; Myasthenia Gravis; Nivolumab; Prednisone | 2021 |
Exacerbation Rate in Generalized Myasthenia Gravis and Its Predictors.
Topics: Autoantibodies; Humans; Male; Myasthenia Gravis; Prednisone; Receptors, Cholinergic; Retrospective S | 2021 |
Ocular myasthenia gravis - How effective is low dose prednisone long term?
Topics: Humans; Myasthenia Gravis; Prednisone; Pyridostigmine Bromide; Retrospective Studies; Treatment Outc | 2021 |
Pediatric Autoimmune Ocular Myasthenia Gravis: Evaluation of Presentation and Treatment Outcomes in a Large Cohort.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Cholinesterase Inhibitors; Disease Progression; Fe | 2021 |
Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis.
Topics: Humans; Immunoglobulins, Intravenous; Myasthenia Gravis; Prednisone; Retrospective Studies | 2021 |
Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report.
Topics: Aged; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Humans; Immunocompro | 2021 |
Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients ≥65 years old.
Topics: Aged; Humans; Immunologic Factors; Myasthenia Gravis; Prednisone; Retrospective Studies; Rituximab | 2021 |
Clinical evaluation of efficacy of leflunomide combined with low-dose prednisone for treatment of myasthenia gravis.
Topics: Humans; Leflunomide; Myasthenia Gravis; Prednisone; Treatment Outcome | 2023 |
Pattern of ocular involvement in myasthenia gravis with MuSK antibodies.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Autoantibodies; Child; Child, Preschool; Diplopia; Eye; | 2017 |
Prompt Response to Prednisone Predicts Benign Course in MuSK-MG.
Topics: Adult; Anti-Inflammatory Agents; Autoantibodies; Female; Humans; Male; Middle Aged; Myasthenia Gravi | 2017 |
Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis.
Topics: Adult; Anti-Inflammatory Agents; Antigens, CD; Autoantibodies; Dose-Response Relationship, Drug; Fem | 2017 |
Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Topics: Adolescent; Anti-Inflammatory Agents; Antibodies; Child; Cohort Studies; Dose-Response Relationship, | 2017 |
[Analysis for the effect of different regimens on ocular myasthenia gravis in children].
Topics: Child; Cholinesterase Inhibitors; Eye Diseases; Glucocorticoids; Humans; Methylprednisolone; Myasthe | 2017 |
Neostigmine: Not Only for the Operating Room.
Topics: Aged, 80 and over; Anti-Inflammatory Agents; Cholinesterase Inhibitors; Emergency Nursing; Emergency | 2018 |
Clinical trials for myasthenia gravis: a historical perspective.
Topics: Enzyme Inhibitors; History, 20th Century; Humans; Immunosuppressive Agents; Myasthenia Gravis; Mycop | 2018 |
Myasthenic ophthalmoparesis: Time To resolution after initiating immune therapies.
Topics: Adult; Azathioprine; Female; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Immunologic Fact | 2018 |
Histopathology of thymectomy specimens from the MGTX-trial: Entropy analysis as strategy to quantify spatial heterogeneity of lymphoid follicle and fat distribution.
Topics: Adult; Aged; Entropy; Female; Humans; Lymphadenopathy; Male; Middle Aged; Myasthenia Gravis; Prednis | 2018 |
Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis.
Topics: Activities of Daily Living; Adult; Aged; Cohort Studies; Female; Humans; Immunosuppressive Agents; M | 2018 |
Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Dose-Response Relationship, Drug; Female; Humans; Longitudina | 2018 |
Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis.
Topics: Adolescent; Adult; Age of Onset; Aged; Child; Cohort Studies; Female; Humans; Immunoglobulins, Intra | 2019 |
Thymectomy in myasthenia gravis: when, why, and how?
Topics: Humans; Myasthenia Gravis; Prednisone; Scorpion Venoms; Thymectomy | 2019 |
Multimodality therapy for thymoma patients with pleural dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; | 2019 |
Successful use of an immune checkpoint inhibitor in a patient with myasthenia gravis in remission.
Topics: Antineoplastic Agents, Immunological; Azathioprine; Central Nervous System Neoplasms; Cholinesterase | 2019 |
Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis.
Topics: Adolescent; Adult; Age Factors; Aged; Autoantibodies; Child; Child, Preschool; China; Cholinesterase | 2019 |
A 23-Year-Old Man With Dyspnea During Myasthenia Crisis.
Topics: Diaphragm; Dyspnea; Humans; Immunosuppressive Agents; Male; Myasthenia Gravis; Mycophenolic Acid; Ox | 2019 |
Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies; Cholinesterase Inhibitors; Coh | 2019 |
Baseline Decrement in Patients with Mild Myasthenia Gravis Predicts Immunomodulation Treatment.
Topics: Adult; Aged; Azathioprine; Electromyography; Female; Humans; Immunoglobulins, Intravenous; Immunosup | 2019 |
Invasive thymoma in ocular myasthenia gravis: diagnostic and prognostic implications.
Topics: Anti-Inflammatory Agents; Female; Humans; Male; Myasthenia Gravis; Prednisone | 2013 |
The effect of steroid treatment and thymectomy on bone age and height development in juvenile myasthenia gravis.
Topics: Adolescent; Body Height; Bone Diseases, Developmental; Cross-Sectional Studies; Female; Growth Disor | 2013 |
Systemic inflammatory pseudotumor and myasthenia gravis.
Topics: Antibodies, Monoclonal, Murine-Derived; Drug Therapy, Combination; Electromyography; Glucocorticoids | 2014 |
Double seropositive myasthenia gravis with acetylcholine receptor and lipoprotein receptor-related protein 4 antibodies.
Topics: Aged; Antibodies; Humans; LDL-Receptor Related Proteins; Male; Myasthenia Gravis; Neuromuscular Junc | 2014 |
The effects of prednisone and steroid-sparing agents on decay accelerating factor (CD55) expression: implications in myasthenia gravis.
Topics: Animals; Azathioprine; CD55 Antigens; Cell Line; Chlorocebus aethiops; COS Cells; Cyclosporine; Gluc | 2014 |
Resolution of severe obstructive sleep apnea after treatment of anti-muscle kinase receptor-positive myasthenia gravis despite 60-pound weight gain.
Topics: Anti-Inflammatory Agents; Female; Follow-Up Studies; Humans; Middle Aged; Myasthenia Gravis; Mycophe | 2014 |
Double seronegative myasthenia gravis with low density lipoprotein-4 (LRP4) antibodies presenting with isolated ocular symptoms.
Topics: Adult; Aged, 80 and over; Blepharoptosis; Cholinesterase Inhibitors; Diplopia; Drug Therapy, Combina | 2014 |
Presacral Mass Discovered during Pregnancy followed by Myasthenia Gravis.
Topics: Adult; Azathioprine; Castleman Disease; Cholinesterase Inhibitors; Female; Humans; Immunosuppressive | 2015 |
Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Autoantibodies; Cholinesterase Inhibitor | 2016 |
Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study.
Topics: Activities of Daily Living; Adolescent; Adult; Drug Therapy, Combination; Female; Follow-Up Studies; | 2016 |
Disease specific enrichment of circulating let-7 family microRNA in MuSK+ myasthenia gravis.
Topics: Adult; Aged, 80 and over; Anti-Inflammatory Agents; Autoantibodies; Case-Control Studies; Electromyo | 2016 |
Ptosis Repair in Ocular Myasthenia Gravis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Blepharoplasty; Blepharoptosis; Cholineste | 2017 |
Spontaneous resolution of a mediastinal mass in a woman with myasthenia gravis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Azathioprine; Cholinesterase Inhib | 2018 |
RetroSternal--Looking Back at Thymectomy for Myasthenia Gravis.
Topics: Female; Glucocorticoids; Humans; Male; Myasthenia Gravis; Prednisone; Thymectomy | 2016 |
Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab.
Topics: Adult; Age of Onset; Aged; Anti-Inflammatory Agents; Antibodies; Diabetes Complications; Diabetes Me | 2016 |
Letter re: A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
Topics: Humans; Methotrexate; Myasthenia Gravis; Prednisone | 2017 |
Letter re: A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
Topics: Humans; Methotrexate; Myasthenia Gravis; Prednisone | 2017 |
Anti-LRP4 autoantibodies in Chinese patients with myasthenia gravis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Asian People; Autoantibodies; Cholinesterase Inhibitors | 2017 |
Muscle weakness in a girl with autoimmune hepatitis and Graves' disease.
Topics: Autoantibodies; Comorbidity; Diagnosis, Differential; Electromyography; Female; Graves Disease; Hepa | 2009 |
The muddle of mycophenolate mofetil in myasthenia.
Topics: Drug Therapy, Combination; Humans; Immunosuppressive Agents; Myasthenia Gravis; Mycophenolic Acid; P | 2008 |
Dyspnoea due to vocal fold abduction paresis in anti-MuSK myasthenia gravis.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Anti-Idiotypic; Dyspnea; Female; Humans; Laryngoscopy; | 2008 |
Influence of ectopic thymic tissue on clinical outcome following extended thymectomy in generalized seropositive nonthymomatous myasthenia gravis.
Topics: Adipose Tissue; Adolescent; Adult; Aged; Antineoplastic Agents, Hormonal; Choristoma; Combined Modal | 2008 |
Sweet syndrome as a manifestation of azathioprine hypersensitivity.
Topics: Adult; Aged; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Hypersensitivity; Humans; Immuno | 2008 |
Course and outcome of a voltage-gated potassium channel antibody negative Morvan's syndrome.
Topics: Adrenal Cortex Hormones; Autoantibodies; Humans; Male; Middle Aged; Myasthenia Gravis; Myokymia; Pla | 2009 |
Graded response to thymectomy in children with myasthenia gravis.
Topics: Adolescent; Adult; Age Distribution; Child; Child, Preschool; Cholinesterase Inhibitors; Cohort Stud | 2009 |
T-cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gravis.
Topics: Aged; Biomarkers; Epstein-Barr Virus Infections; Female; Genitalia, Female; Gingiva; Gingivitis; Hum | 2009 |
Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up.
Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Child; Child, Pr | 2009 |
Late onset generalized myasthenia gravis presenting with facial weakness and bulbar signs without extraocular muscle involvement.
Topics: Action Potentials; Aged; Anti-Inflammatory Agents; Cholinesterase Inhibitors; Deglutition Disorders; | 2009 |
Unsatisfactory outcomes in myasthenia gravis: influence by care providers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Child; Cholinesterase Inhibitors; Clinical | 2010 |
Rituximab in the management of refractory myasthenia gravis.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cholineste | 2010 |
Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience.
Topics: Adolescent; Adult; Age of Onset; Aged; Child; Disease-Free Survival; Electromyography; Female; Human | 2010 |
Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis.
Topics: Age Factors; Age of Onset; Aged; Aged, 80 and over; Azathioprine; Chi-Square Distribution; Cyclospor | 2010 |
Myasthenia gravis and return to flying status.
Topics: Adult; Aerospace Medicine; Cholinesterase Inhibitors; Disease Progression; Glucocorticoids; Health S | 2010 |
Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 2010 |
Diagnostic challenge: Myasthenia gravis in the emergency department.
Topics: Adult; Cholinesterase Inhibitors; Emergency Service, Hospital; Glucocorticoids; Humans; Male; Myasth | 2010 |
Thymoma-associated myasthenia gravis without acetylcholine receptor antibodies.
Topics: Action Potentials; Anti-Inflammatory Agents; Autoantibodies; Azathioprine; Electric Stimulation; Evo | 2011 |
[Clinical characteristics and follow-up management of 135 children with myasthenia gravis].
Topics: Adolescent; Age of Onset; Antibodies; Child; Child, Preschool; Female; Follow-Up Studies; Humans; In | 2011 |
The importance of studying history: lessons learnt from a trial of tacrolimus in myasthenia gravis.
Topics: Anti-Inflammatory Agents; Biomarkers; Humans; Immunosuppressive Agents; Interleukin-2; Myasthenia Gr | 2011 |
Childhood myasthenia gravis: clinical features and outcomes.
Topics: Adolescent; Age of Onset; Anti-Inflammatory Agents; Blepharoptosis; Child; Child, Preschool; Choline | 2011 |
Myasthenia gravis and endurance exercise.
Topics: Athletes; Cholinesterase Inhibitors; Deglutition Disorders; Fatigue; Glucocorticoids; Humans; Male; | 2012 |
Safety of prednisone for ocular myasthenia gravis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Female; Humans; Longitudinal S | 2012 |
[Myasthenia--ocular type].
Topics: Diagnosis, Differential; Diplopia; Female; Follow-Up Studies; Glucocorticoids; Humans; Medication Ad | 2011 |
The characteristics of juvenile myasthenia gravis among South Africans.
Topics: Adolescent; Adult; Age of Onset; Analysis of Variance; Antibodies; Child; Child, Preschool; Eye Dise | 2012 |
Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature.
Topics: Airway Extubation; Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antigens, CD19; | 2012 |
Possible involvement of toll-like receptors in the pathogenesis of myasthenia gravis.
Topics: Humans; Leukocytes, Mononuclear; Myasthenia Gravis; Prednisone; RNA, Messenger; Toll-Like Receptor 9 | 2013 |
Unusual case of recurrent falls: myasthenia gravis in an elderly patient.
Topics: Accidental Falls; Aged, 80 and over; Antibodies; Blepharoptosis; Cholinesterase Inhibitors; Dysarthr | 2012 |
Management challenges in muscle-specific tyrosine kinase myasthenia gravis.
Topics: Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Glucocorticoids; Humans; Myasthenia Gravis; | 2012 |
A relapsing-remitting type of ocular myasthenia gravis without typical muscle fatiguability.
Topics: Adult; Diagnosis, Differential; Electromyography; Female; Follow-Up Studies; Humans; Male; Middle Ag | 2002 |
In myasthenia gravis, clinical and immunological improvement post-thymectomy segregate with results of in vitro antibody secretion by immunocytes.
Topics: Adult; Anti-Inflammatory Agents; Autoantibodies; Cell Culture Techniques; Cholinesterase Inhibitors; | 2002 |
Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodi | 2003 |
Autoimmune myasthenia gravis after cardiac surgery.
Topics: Aged; Anti-Inflammatory Agents; Antibodies; Cholinesterase Inhibitors; Coronary Artery Bypass; Human | 2003 |
Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
Topics: Adolescent; Adult; Age of Onset; Aged; Autoantibodies; Azathioprine; Case-Control Studies; Child; Cy | 2003 |
Childhood ocular myasthenia gravis.
Topics: Amblyopia; Blepharoptosis; Child; Child, Preschool; Diagnostic Techniques, Ophthalmological; Drug Th | 2003 |
Use of prednisone in myasthenia gravis in a diabetic.
Topics: Diabetes Complications; Diabetes Mellitus; Humans; Myasthenia Gravis; Prednisone | 1958 |
THYMOMA AND POLYMYOSITIS. ONSET OF MYASTHENIA GRAVIS AFTER THYMECTOMY: REPORT OF TWO CASES.
Topics: Aspartate Aminotransferases; Autoimmune Diseases; Biopsy; Cortisone; Electromyography; Humans; Myast | 1964 |
MYASTHENIA GRAVIS AND SYSTEMIC LUPUS ERYTHEMATOSUS.
Topics: Arthritis; Autoantibodies; Autoimmune Diseases; Hemagglutination; Humans; Lupus Erythematosus, Syste | 1964 |
Myasthenia gravis: generalized vs ocular, and children vs adults.
Topics: Adult; Anti-Inflammatory Agents; Child; Eye Diseases; Humans; Myasthenia Gravis; Prednisone | 2003 |
Acquired rippling muscle disease with myasthenia gravis.
Topics: Adult; Alopecia Areata; Antineoplastic Agents; Electromyography; Humans; Male; Muscle Contraction; M | 2004 |
Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease?
Topics: Disease Progression; Drug Administration Schedule; Humans; Immunosuppressive Agents; Myasthenia Grav | 2004 |
The effect of prednisone on the progression from ocular to generalized myasthenia gravis.
Topics: Cholinesterase Inhibitors; Disease Progression; Dose-Response Relationship, Drug; Drug Administratio | 2004 |
Safety for preoperative use of steroids for transsternal thymectomy in myasthenia gravis.
Topics: Adult; Female; Humans; Male; Morbidity; Myasthenia Gravis; Postoperative Complications; Prednisone; | 2004 |
Cryptococcal cellulitis in a patient on prednisone monotherapy for myasthenia gravis.
Topics: Administration, Cutaneous; Cellulitis; Cryptococcosis; Cryptococcus neoformans; Female; Glucocortico | 2004 |
Myasthenia gravis: how to treat?
Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Drug Therapy, Combination; Female; Glucocorticoi | 2004 |
Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; CD4-Positive T-Lymphocytes; Cross-Sectiona | 2005 |
Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Ag | 2005 |
High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies.
Topics: Alkylating Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine- | 2006 |
Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blepharoptosis; Child; Child, Preschool; Cholinesterase | 2005 |
Eosinophilia, myositis, and myasthenia gravis associated with a thymoma.
Topics: Aged; Anti-Inflammatory Agents; Blood Cell Count; Cholinesterase Inhibitors; Eosinophilia; Eye Movem | 2006 |
Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis.
Topics: Cohort Studies; Cyclosporine; Humans; Myasthenia Gravis; Prednisone; Research Design; Tacrolimus; Ti | 2006 |
Preoperative use of steroids in patients with myasthenia gravis.
Topics: Combined Modality Therapy; Glucocorticoids; Humans; Myasthenia Gravis; Prednisone; Thymectomy | 2006 |
Is taking preoperative high-dose steroid necessary?
Topics: Glucocorticoids; Humans; Myasthenia Gravis; Patient Selection; Prednisone; Preoperative Care; Thymec | 2006 |
Clinical predictors of steroid-induced exacerbation in myasthenia gravis.
Topics: Adult; Age Factors; Anti-Inflammatory Agents; Brain Stem; Disability Evaluation; Female; Humans; Mal | 2006 |
Perioral dermatitis in a patient with myasthenia gravis following systemic corticosteroid treatment.
Topics: Administration, Oral; Adult; Dermatitis, Perioral; Drug Eruptions; Female; Glucocorticoids; Humans; | 2007 |
Myasthenia gravis: an unrecognized cause of head drop in Parkinson's disease.
Topics: Anti-Inflammatory Agents; Antiparkinson Agents; Cholinesterase Inhibitors; Electromyography; Female; | 2008 |
Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantibo | 2007 |
Is cerebral involvement an occasional feature of muscle-specific kinase antibody-positive syndrome?
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Autoantibodies; Brain; Cho | 2007 |
Treatment of a patient with myasthenia gravis using antibodies against CD25.
Topics: Adult; Antibodies, Monoclonal; Antigens, Surface; Basiliximab; Cyclosporine; Cytokines; Drug Therapy | 2008 |
Thymopoiesis, regulatory T cells, and TCRVbeta expression in thymoma with and without myasthenia gravis, and modulatory effects of steroid therapy.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antigens, CD; CD3 Complex; CD4 Lymphocyte Count; C | 2008 |
Treating ocular Myasthenia Gravis with inadequate evidence.
Topics: Combined Modality Therapy; Eye Diseases; Humans; Immunosuppressive Agents; Myasthenia Gravis; Predni | 2007 |
[Development of a myasthenia crisis during interferon treatment for chronic C hepatitis].
Topics: Aged; Antiviral Agents; Cholinesterase Inhibitors; Follow-Up Studies; Glucocorticoids; Hepatitis C, | 2007 |
Long-term clinical outcome after extended thymectomy combined postoperative high-dose steroid therapy for juvenile myasthenia gravis.
Topics: Adolescent; Child; Cholinesterase Inhibitors; Combined Modality Therapy; Glucocorticoids; Humans; Ma | 2008 |
Myasthenia gravis and pregnancy: a reappraisal of thymectomy.
Topics: Adolescent; Adult; Female; Humans; Myasthenia Gravis; Prednisone; Pregnancy; Pregnancy Complications | 1983 |
Eaton-Lambert myasthenic syndrome: long-term treatment of three patients with prednisone.
Topics: Adolescent; Dose-Response Relationship, Drug; Electromyography; Female; Humans; Long-Term Care; Male | 1981 |
Reversal of apparent premature ovarian failure in a patient with myasthenia gravis.
Topics: Adult; Azathioprine; Estrogens, Conjugated (USP); Female; Humans; Menstruation Disturbances; Myasthe | 1983 |
Absence of decremental response in decentralized muscles of a myasthenic patient.
Topics: Aged; Azathioprine; Drug Therapy, Combination; Female; Humans; Myasthenia Gravis; Neuromuscular Junc | 1983 |
Corticosteroids in autoimmune disease.
Topics: Adrenal Cortex Hormones; Autoimmune Diseases; Circadian Rhythm; Cyclophosphamide; Dermatomyositis; D | 1983 |
[Large dose of prednisone in the treatment of the oculomuscular type of myasthenia gravis].
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Oc | 1984 |
Development of systemic lupus erythematosus after thymectomy for myasthenia gravis. Studies of suppressor cell function.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Humans; Immunologic Techniques; In Vitro Techniques; Lup | 1981 |
[Amount of circulating acetylcholine receptor antibodies in the course of myasthenia, following thymectomy and in immunosuppressive therapy].
Topics: Adult; Autoantibodies; Azathioprine; Drug Therapy, Combination; Female; Humans; Male; Myasthenia Gra | 1984 |
[Correlation of acetylcholine receptor antibodies and clinical severity of myasthenia gravis in combined immunosuppressive therapy].
Topics: Adult; Autoantibodies; Azathioprine; Combined Modality Therapy; Dose-Response Relationship, Drug; Dr | 1984 |
Myasthenia gravis: prolonged treatment with steroids.
Topics: Adolescent; Adult; Aged; Critical Care; Dexamethasone; Female; Humans; Male; Middle Aged; Myasthenia | 1984 |
[Antibody-controlled cytostatic therapy of malignant thymoma with concomitant myasthenia gravis].
Topics: Acetylcholine; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Cyclophosph | 1984 |
The in vivo effects of corticosteroids on thymocyte subsets in myasthenia gravis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aging; Antibodies, Monoclonal; Female; Humans; Male; Mid | 1984 |
Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Drug Administration Schedule; Female; Humans; Male; Mid | 1984 |
Clinical remission after corticosteroid therapy of acquired myasthenia in three dogs.
Topics: Adrenal Cortex Hormones; Animals; Dog Diseases; Dogs; Female; Male; Myasthenia Gravis; Prednisone | 1984 |
Azathioprine in the treatment of myasthenia gravis.
Topics: Adult; Aged; Azathioprine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Huma | 1984 |
Jaw claudication. Its value as a diagnostic clue.
Topics: Aged; Arthritis, Rheumatoid; Diagnosis, Differential; Female; Giant Cell Arteritis; Humans; Jaw Dise | 1983 |
Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients.
Topics: Adolescent; Adult; Aged; Autoantibodies; Azathioprine; Child; Chlorambucil; Female; Humans; Male; Mi | 1983 |
Myasthenia gravis in the elderly: report of 37 cases.
Topics: Aged; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisone; Pyridosti | 1983 |
Myasthenia gravis in children: long-term follow-up.
Topics: Adolescent; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; Male; Myasthenia Gra | 1983 |
[Low-dosage prednisone in myasthenia gravis].
Topics: Aged; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisone | 1983 |
Effect of immunosuppressive drugs (azathioprine).
Topics: Adult; Azathioprine; Humans; Myasthenia Gravis; Prednisone; Thymectomy | 1981 |
Response to plasmapheresis and immunosuppressive drug therapy in sixty myasthenia gravis patients.
Topics: Adult; Aged; Azathioprine; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Male; Middle | 1981 |
Effect of plasmapheresis in myasthenia gravis.
Topics: Adolescent; Adult; Aged; Antibodies; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; M | 1981 |
Binding affinities of anti-acetylcholine receptor autoantibodies in myasthenia gravis.
Topics: Acetylcholine; Antibody Affinity; Autoantibodies; Binding Sites, Antibody; Humans; Myasthenia Gravis | 1982 |
The ocular signs and symptoms of myasthenia gravis.
Topics: Adolescent; Adult; Aged; Antibodies; Blepharoptosis; Child; Child, Preschool; Cholinesterase Inhibit | 1982 |
Thymectomy for myasthenia gravis: a changing perspective.
Topics: Adult; Female; Humans; Male; Myasthenia Gravis; Postoperative Care; Prednisone; Preoperative Care; T | 1982 |
Plasmapheresis: a new treatment modality for the patient with severe myasthenia gravis.
Topics: Azathioprine; Cholinesterase Inhibitors; Humans; Male; Middle Aged; Myasthenia Gravis; Plasmapheresi | 1982 |
Plasmapheresis in myasthenia gravis.
Topics: Adult; Aged; Autoantibodies; Azathioprine; Chlorambucil; Cyclophosphamide; Female; Humans; Immunosup | 1982 |
Plasma exchange combined with cytotoxic drugs and lymphocytapheresis for myasthenia gravis.
Topics: Azathioprine; Cell Separation; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Leukapher | 1982 |
[Myasthenia gravis--treatment with prednisone].
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisone | 1982 |
Humoral immunity in myasthenia gravis: effect of steroids and thymectomy.
Topics: Acetylcholine; Adolescent; Adult; Autoantibodies; Child; Dose-Response Relationship, Drug; Humans; M | 1980 |
Juvenile myasthenia gravis.
Topics: Adolescent; Child; Child, Preschool; Eye Manifestations; Female; Humans; Immunoglobulin G; Infant; M | 1980 |
Stable remissions in myasthenia gravis.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Male; Middle A | 1981 |
Psychiatric effects of alternate day steroid therapy.
Topics: Adult; Affective Symptoms; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myasthen | 1981 |
The effect of plasmapheresis on post-thymectomy ocular dysfunction.
Topics: Adult; Antibodies; Blepharoptosis; Eye Diseases; Humans; Middle Aged; Myasthenia Gravis; Plasmaphere | 1981 |
[Myasthenia gravis in a young dog (author's transl)].
Topics: Animals; Atropine Derivatives; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Myasthenia Gra | 1981 |
Myasthenia gravis in children: long-term follow-up.
Topics: Adolescent; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; Male; Myasthenia Gra | 1981 |
Myasthenia gravis.
Topics: Adrenal Cortex Hormones; Adult; Female; Humans; Male; Myasthenia Gravis; Plasmapheresis; Postoperati | 1980 |
Thymectomy for myasthenia gravis in the young adult. Long-term results.
Topics: Adolescent; Adult; Age Factors; Child; Cholinesterase Inhibitors; Female; Humans; Middle Aged; Myast | 1980 |
[Treatment of myasthenia gravis--pathophysiological evaluation of various forms of treatment and practical aspects of therapy (author's transl)].
Topics: Azathioprine; Cholinesterase Inhibitors; Evaluation Studies as Topic; Humans; Myasthenia Gravis; Pla | 1980 |
Glucocorticoid therapy for myasthenia gravis resulting in resorption of the mandibular condyles.
Topics: Adult; Bone Resorption; Female; Humans; Mandibular Condyle; Mandibular Diseases; Myasthenia Gravis; | 1995 |
Atrophy of the tongue with persistent articulation disorder in myasthenia gravis: report of 10 patients.
Topics: Adult; Age of Onset; Articulation Disorders; Deglutition Disorders; Female; Humans; Immunosuppressiv | 1994 |
Exotropia as a sign of myasthenia gravis in dysthyroid ophthalmopathy.
Topics: Adult; Blepharoptosis; Exotropia; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisone; | 1993 |
Myasthenia gravis and scleroderma.
Topics: Adult; Antibodies, Antinuclear; Female; Humans; Myasthenia Gravis; Prednisone; Pyridostigmine Bromid | 1993 |
Single fiber electromyography in myasthenia gravis during pregnancy.
Topics: Adult; Blepharoptosis; Diplopia; Electromyography; Female; Humans; Myasthenia Gravis; Prednisone; Pr | 1993 |
[Effects of thymectomy and glucocorticoid therapy on peripheral lymphocytes in myasthenia gravis].
Topics: Adolescent; Adult; Autoantibodies; CD4-CD8 Ratio; Child; Female; Humans; Male; Middle Aged; Myasthen | 1995 |
Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients.
Topics: Age of Onset; Aged; Autoimmune Diseases; Azathioprine; Cholinesterase Inhibitors; Cohort Studies; Di | 1997 |
[Favorable results of plasmapheresis in severe myasthenia gravis].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Female; Humans; Male; Middle | 1997 |
Dramatic response of postthymomectomy myasthenia gravis with multiple lung nodules to corticosteroids.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Therapy, Combination; Fem | 1997 |
Myasthenia gravis and alopecia areata.
Topics: Adolescent; Alopecia Areata; Cholinesterase Inhibitors; Female; Humans; Myasthenia Gravis; Prednison | 1998 |
[Ocular myasthenia: clinical course and strategies for treatment].
Topics: Adult; Aged; Anti-Inflammatory Agents; Blepharoptosis; Cholinesterase Inhibitors; Diplopia; Female; | 1998 |
Seronegative myasthenia gravis and human immunodeficiency virus infection: response to intravenous gamma globulin and prednisone.
Topics: Adult; Anti-Inflammatory Agents; Edrophonium; Electroencephalography; Electrophysiology; gamma-Globu | 1998 |
[Treatment of myasthenia: role of corticoids and immunosuppressive agents].
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Azathioprine; Cyclosporins; | 1999 |
Tiopronin-induced myasthenia.
Topics: Aged; Arthritis, Rheumatoid; Female; Humans; Myasthenia Gravis; Neostigmine; Parasympathomimetics; P | 1999 |
Multiple myeloma in the breast.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Doxorubicin; Fatal | 1999 |
Myasthenia gravis and peripheral neuropathy in an Amazon indigenous female.
Topics: Adult; Anti-Inflammatory Agents; Brazil; Female; Humans; Indians, South American; Myasthenia Gravis; | 1999 |
Pseudo-myasthenia gravis and thymic hyperplasia in Graves' disease.
Topics: Adult; Anti-Anxiety Agents; Anti-Inflammatory Agents; Antithyroid Agents; Diagnosis, Differential; F | 1999 |
The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children.
Topics: Adolescent; Blepharoptosis; Child; Child, Preschool; Cholinesterase Inhibitors; Disease Progression; | 2000 |
Myasthenia gravis with a paraneoplastic marker.
Topics: Autoantibodies; Azathioprine; Biomarkers; Blepharoptosis; Calcium Channels; Carcinoma, Large Cell; D | 2000 |
Dysphagia with multiple autoimmune disease.
Topics: Aged; Anti-Inflammatory Agents; Biopsy; Deglutition Disorders; Diagnosis, Differential; Esophageal A | 2000 |
A severe case of myasthenia gravis during pregnancy.
Topics: Adult; Cesarean Section; Cholinesterase Inhibitors; Female; Gestational Age; Humans; Myasthenia Grav | 2000 |
Clinical characteristics and prognosis of myasthenia gravis in older people.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Azathioprine; Cholinesterase Inhibitors; Drug The | 2000 |
Myasthenia gravis in a collegiate football player.
Topics: Adolescent; Athletic Injuries; Blepharoptosis; Football; Glucocorticoids; Humans; Male; Myasthenia G | 2000 |
Effect of thymectomy on human peripheral blood T cell pools in myasthenia gravis.
Topics: Adolescent; Adult; Azathioprine; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocyt | 2001 |
Myasthenia gravis with ocular involvement in older patients.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Drug Therapy, Combination; Eye Diseases; Female; | 2001 |
Analysis of thymectomy for myasthenia gravis in older patients: a 20-year single institution experience.
Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Child; Child, Preschool; Combined Modality Thera | 2001 |
Myasthenia gravis in children: analysis of 18 patients.
Topics: Age of Onset; Child; Child, Preschool; Cholinesterase Inhibitors; Female; Follow-Up Studies; Humans; | 2001 |
High-dose immunosuppressive therapy in generalised myasthenia gravis--a 2-year follow-up study.
Topics: Anti-Inflammatory Agents; Azathioprine; Dose-Response Relationship, Drug; Drug Administration Schedu | 2001 |
[Effect of immunologic treatment on lymphocyte subsets in patients with myasthenia gravis].
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Drug Therapy, Combination; Female; Glucocorticoids | 1999 |
[Tacrolimus (FK506) in the treatment of prednisone-resistant myasthenia gravis. Preliminary results of 20 cases].
Topics: Adult; Drug Resistance; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Myasthenia | 2002 |
Thymectomy by thoracoscopic approach in myasthenia gravis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Child; Cholinesterase Inhibitors; Female; Humans; Immun | 2002 |
Remission of myasthenia gravis following plasma-exchange.
Topics: Adult; Autoantibodies; Autoimmune Diseases; Azathioprine; Cyclophosphamide; Evaluation Studies as To | 1976 |
Humoral immunity in myasthenia gravis: relationship to disease severity and steroid treatment.
Topics: Animals; Autoimmune Diseases; Binding Sites, Antibody; Cholinesterase Inhibitors; Humans; Immunoglob | 1978 |
Long-term effects of repeated plasma exchange in myasthenia gravis.
Topics: Acetylcholine; Adolescent; Adult; Antibody Formation; Autoantibodies; Autoimmune Diseases; Azathiopr | 1979 |
Combined plasma exchange and immunosuppression in myasthenia gravis.
Topics: Azathioprine; Follow-Up Studies; Humans; Male; Myasthenia Gravis; Plasmapheresis; Prednisone; Time F | 1979 |
Treatment of myasthenia gravis. Report on 139 patients.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Female; Follow-Up Studies; Humans; Male | 1979 |
Myasthenia gravis and monoclonal IgG gammopathy.
Topics: Acetylcholine; Antibodies, Anti-Idiotypic; Blood Protein Electrophoresis; Cyclophosphamide; Drug The | 1979 |
[Treatment in myasthenic crisis induced by ACTH (author's transl)].
Topics: Adrenocorticotropic Hormone; Humans; Myasthenia Gravis; Prednisone; Respiration, Artificial | 1975 |
Steroid therapy of myasthenia gravis.
Topics: Adrenocorticotropic Hormone; Humans; Myasthenia Gravis; Prednisone | 1975 |
Rapid eye movement sleep alterations in myasthenia gravis.
Topics: Adult; Aged; Brain; Electroencephalography; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Pr | 1976 |
Corticotropin and corticosteroids in generalized myasthenia gravis: comparative studies and role in management.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Aged; Child; Dexamethasone; | 1976 |
[Therapy of myasthenia gravis].
Topics: Adrenocorticotropic Hormone; Azathioprine; Cholinesterase Inhibitors; Drainage; Humans; Immunosuppre | 1977 |
Myasthenia in patients with dermatomyositis: clinical, electrophysiological and ultrastructural studies.
Topics: Adolescent; Adult; Biopsy; Dermatomyositis; Electromyography; Evoked Potentials; Fatigue; Female; Gl | 1978 |
Symposium on therapeutic controversies. Myasthenia gravis. Steroids and immunosuppressive drugs.
Topics: Adrenocorticotropic Hormone; Aged; Azathioprine; Humans; Myasthenia Gravis; Prednisone | 1978 |
Polymyositis and dermatomyositis: clinical problems.
Topics: Collagen Diseases; Dermatomyositis; Diagnosis, Differential; Humans; Myasthenia Gravis; Myositis; Ne | 1978 |
Current views on the treatment of myasthenia gravis: with particular reference to immunological mechanisms.
Topics: Adolescent; Adult; Aged; Animals; Dexamethasone; Humans; Immunosuppression Therapy; Mice; Middle Age | 1978 |
Myasthenia gravis in a Papua New Guinean.
Topics: Adult; Cholinesterase Inhibitors; Humans; Male; Myasthenia Gravis; Neostigmine; New Guinea; Predniso | 1979 |
Prednisone use in concurrent autoimmune diseases.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Autoimmune Diseases; Creatine Kinase; Dose | 1979 |
Myasthenia gravis: pathogenesis, diagnosis, and therapy.
Topics: Adult; Autoimmune Diseases; Cholinesterase Inhibitors; Electromyography; Female; Humans; Infant, New | 1979 |
Humoral immunity in myasthenia gravis: relationship to disease severity and steroid treatment.
Topics: Acetylcholine; Autoantibodies; Female; Humans; Male; Myasthenia Gravis; Prednisone; Receptors, Choli | 1979 |
[Treatment of myasthenia gravis with plasmapheresis (author's transl)].
Topics: Adolescent; Adult; Azathioprine; Cyclophosphamide; Female; Humans; Male; Middle Aged; Myasthenia Gra | 1979 |
Dexamethasone dosage suggested every 3-4 days in myasthenia gravis.
Topics: Dexamethasone; Humans; Myasthenia Gravis; Prednisone | 1977 |
Effective treatment of infantile myasthenia gravis by combined prednisone and thymectomy.
Topics: Age Factors; Child, Preschool; Female; Humans; Male; Myasthenia Gravis; Prednisone; Thymectomy | 1977 |
Caution urged in childhood thymectomy for myasthenia gravis.
Topics: Age Factors; Child; Humans; Myasthenia Gravis; Prednisone; Thymectomy | 1977 |
Cellular immune response to acetylcholine receptor in myasthenia gravis: II. Thymectomy and corticosteroids.
Topics: Acetylcholine; Adolescent; Adult; Animals; Dexamethasone; Female; Fishes; Humans; Immunity, Cellular | 1979 |
Research findings of potential value to the practitioner.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Child, Preschool; Female; Humans; Infant; Infant, Newbo | 1977 |
High-dose steroids for perioperative management of patients with myasthenia gravis undergoing thymectomy. A preliminary report.
Topics: Adolescent; Adult; Critical Care; Drug Evaluation; Humans; Infusions, Parenteral; Length of Stay; Me | 1978 |
Essentials in the management of myasthenia gravis.
Topics: Cholinesterase Inhibitors; Edrophonium; Humans; Muscles; Myasthenia Gravis; Prednisone; Thymectomy | 1978 |
[Myasthenia gravis (3). Corticosteroid therapy of myasthenia gravis].
Topics: HLA Antigens; Humans; Myasthenia Gravis; Prednisone; Time Factors | 1978 |
[Myasthenia gravis: treatment with massive doses of corticosteroids and thymectomy].
Topics: Adult; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisone; Thymectomy | 1978 |
Pemphigus and myasthenia gravis.
Topics: Animals; Antibodies, Antinuclear; Autoantibodies; Cattle; Complement C1; Complement C3; Cross Reacti | 1975 |
Long-term administration of corticosteroids in myasthenia gravis.
Topics: Adolescent; Adult; Aged; Cholinesterase Inhibitors; Drug Administration Schedule; Drug Therapy, Comb | 1976 |
Treatment of myasthenia gravis: long-term administration of corticosteroids with remarks on thymectomy.
Topics: Adolescent; Adult; Aged; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Muscles; Myas | 1977 |
Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.
Topics: Acetylcholine; Adult; Autoantibodies; Azathioprine; Female; Humans; Male; Middle Aged; Myasthenia Gr | 1977 |
Effects of alternate-day prednisone therapy on respiratory function in myasthenia gravis.
Topics: Adolescent; Adult; Aged; Carbon Dioxide; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Oxyge | 1976 |
Trends in therapy: prednisone for myasthenia gravis.
Topics: Humans; Myasthenia Gravis; Prednisone | 1976 |
Long-term prednisone followed by thymectomy in myasthenia gravis.
Topics: Adolescent; Adult; Aged; Cholinesterase Inhibitors; Drug Administration Schedule; Eye Diseases; Fema | 1976 |
Oral corticosteroids in the treatment of ocular myasthenia gravis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Child, Preschool; Eye Diseases; Female; Humans | 1976 |
[The effect of prolonged treatment with prednisone on myasthenia gravis].
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisone | 1975 |
[Corticosteroids in the treatment of myasthenia gravis. Study of 12 cases with review of the literature].
Topics: Administration, Oral; Adolescent; Adult; Dexamethasone; Drug Evaluation; Female; Humans; Male; Middl | 1975 |
Ocular myasthenia gravis and Hashimoto's thyroiditis.
Topics: Adult; Diplopia; Eye Diseases; Female; Goiter; Humans; Myasthenia Gravis; Prednisone; Pyridostigmine | 1975 |
Myasthenia gravis and acetylcholine receptor. Effect of steroids in clinical course and cellular immune response to acetylcholine receptor.
Topics: Acetylcholine; Adolescent; Adult; Aged; Female; Humans; Immunity, Cellular; Lymphocyte Activation; M | 1975 |
Corticosteroid-induced mediastinal widening in myasthenia gravis.
Topics: Humans; Lipomatosis; Male; Mediastinal Diseases; Mediastinal Neoplasms; Mediastinum; Middle Aged; My | 1975 |
Invasive thymoma and myasthenia gravis: a twenty-year experience.
Topics: Female; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisone; Thymectomy; Thymoma; Thymus Neopla | 1975 |
Long-term administration of corticosteroids followed by thymectomy.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisone; Thymectom | 1975 |
Myasthenia gravis and invasive thymoma: a 20-year experience.
Topics: Adult; Aged; Chlorambucil; Cyclophosphamide; Female; Humans; Male; Middle Aged; Myasthenia Gravis; N | 1975 |
Cellular immune response to acetylcholine receptor-rich fraction, in patients with myasthenia gravis.
Topics: Acetylcholine; Adolescent; Adult; Aged; Animals; Cholinesterase Inhibitors; Electrophorus; Female; H | 1975 |
Myasthenia gravis in the elderly.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Child, Preschool; Female; Humans; Infant; Mal | 1976 |
Profile of the regions on the alpha-chain of human acetylcholine receptor recognized by autoantibodies in myasthenia gravis.
Topics: Adolescent; Adult; Aged; Amino Acid Sequence; Autoantibodies; Cyclophosphamide; Epitopes; Female; Hu | 1992 |
[A study of cyclic nucleotide acids in the serum in patients with myasthenia gravis].
Topics: Cyclic AMP; Cyclic GMP; Female; Humans; Male; Myasthenia Gravis; Prednisone; Pyridostigmine Bromide | 1992 |
Long-term results of corticosteroid therapy in patients with myasthenia gravis.
Topics: Adult; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Fe | 1992 |
Immunosuppressive treatment for juvenile myasthenia gravis.
Topics: Adolescent; Adult; Autoimmune Diseases; Azathioprine; Child; Cyclophosphamide; Female; Humans; Immun | 1992 |
Treatment of antenatal myasthenia gravis.
Topics: Administration, Oral; Adult; Antibodies, Anti-Idiotypic; Female; Fetal Diseases; Humans; Infant, New | 1991 |
Effectiveness of steroid treatment in myasthenia gravis: a retrospective study.
Topics: Adolescent; Adult; Aged; Child; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Ad | 1991 |
[Mononuclear cell subsets in the peripheral blood of patients with myasthenia gravis].
Topics: Adolescent; Adult; Antibodies, Monoclonal; B-Lymphocytes; CD4-Positive T-Lymphocytes; Child; Child, | 1990 |
Factors influencing outcome of prednisone dose reduction in myasthenia gravis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Drug Administration Schedule; F | 1991 |
Effect of thymectomy and immunosuppressive therapy on anti-neuroblastoma antibody levels in patients with myasthenia gravis.
Topics: Adolescent; Adult; Aged; Autoantibodies; Azathioprine; Cell Line; Female; Follow-Up Studies; Humans; | 1991 |
Early-onset myasthenia gravis: clinical characteristics and response to therapy.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Cholinesterase Inhibitors; Eye Diseases; Female; F | 1990 |
Myasthenia gravis: regimens and regimen-associated problems in adults.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Clinical Protocols; Humans; | 1990 |
Clinical remission following plasmapheresis and corticosteroid treatment in a dog with acquired myasthenia gravis.
Topics: Animals; Combined Modality Therapy; Dog Diseases; Dogs; Male; Myasthenia Gravis; Plasmapheresis; Pre | 1990 |
Antibody response to pneumococcal polysaccharide vaccine in myasthenia gravis: effect of therapeutic plasmapheresis.
Topics: Adult; Aged; Antibodies, Bacterial; Antigens, Bacterial; Azathioprine; Bacterial Vaccines; Combined | 1990 |
Ocular and systemic myasthenia gravis.
Topics: Blepharoptosis; Diplopia; Eye Diseases; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisone; Py | 1990 |
[Predictive factors of the response to treatment of myasthenia gravis with prednisone].
Topics: Adult; Age Factors; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisone; Prognosis; Sev | 1990 |
Myasthenia gravis.
Topics: Adult; Aged; Female; Humans; Male; Myasthenia Gravis; Prednisone; Thymoma | 1990 |
[Thymectomy and immunosuppression in myasthenia gravis: a prospective study].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Child; Combined Modality Therapy; Fe | 1990 |
Myasthenia gravis.
Topics: Aged; Drug Combinations; Humans; Incidence; Male; Myasthenia Gravis; Prednisone; Pyridostigmine Brom | 1990 |
Widespread pulmonary fibrosis as a major clinical manifestation of chronic graft-versus-host disease.
Topics: Adult; Anemia, Aplastic; Bone Marrow Transplantation; Cyclosporins; Diagnosis, Differential; Graft v | 1989 |
Disseminated thymoma and myasthenia gravis: dramatic response to prednisone.
Topics: Combined Modality Therapy; Female; Humans; Middle Aged; Myasthenia Gravis; Neoplasm Metastasis; Pred | 1989 |
[Intensive therapy of myasthenia gravis].
Topics: Azathioprine; Combined Modality Therapy; Critical Care; Humans; Infusion Pumps; Male; Middle Aged; M | 1988 |
Congenital myasthenia gravis. The clinical spectrum. A practical approach to diagnosis and treatment.
Topics: Autoantibodies; Child; Child, Preschool; Combined Modality Therapy; Drug Therapy, Combination; Edrop | 1988 |
[Treatment of myasthenia].
Topics: Cholinesterase Inhibitors; Humans; Immunosuppressive Agents; Myasthenia Gravis; Plasma Exchange; Pre | 1988 |
Staphylococcal carriage and infection in myasthenia gravis patients receiving therapeutic apheresis.
Topics: Adolescent; Adult; Aged; Blood Component Removal; Drug Administration Schedule; Female; Follow-Up St | 1988 |
Multiple sclerosis, euthyroid restrictive Grave's ophthalmopathy, and myasthenia gravis. A case report.
Topics: Blepharoptosis; Diplopia; Graves Disease; Humans; Injections; Male; Methylprednisolone; Methylpredni | 1988 |
Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Immunologic; Drug Evaluation; Drug Therapy, Com | 1988 |
Myasthenia gravis treatment: twelve years experience on 110 patients.
Topics: Azathioprine; Combined Modality Therapy; Dexamethasone; Humans; Immunosuppressive Agents; Myasthenia | 1987 |
Long-term corticosteroid treatment of myasthenia gravis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Drug Evaluation; Female; Humans; Male; Middle Age | 1987 |
Thymectomy as primary therapy in myasthenia gravis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Cholinesterase Inhibitors; Comb | 1987 |
Blepharospasm and autoimmune diseases.
Topics: Adult; Antibodies, Antinuclear; Autoantibodies; Blepharospasm; Cyclophosphamide; Eyelid Diseases; Fe | 1987 |
Clinical correlates of enzyme-immunoassay versus radioimmunoassay measurements of antibody against acetylcholine receptor in patients with myasthenia gravis.
Topics: Adult; Age Factors; Aged; Autoantibodies; Female; Humans; Immunoenzyme Techniques; Male; Middle Aged | 1986 |
Putative role of antireticulin antibody in antiacetylcholine-receptor-antibody-negative myasthenia gravis.
Topics: Adult; Autoantibodies; Edrophonium; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisone | 1987 |
Factors influencing the relapse risk at steroid dose reduction in myasthenia gravis.
Topics: Azathioprine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Myasthenia Gravis; | 1987 |
Prednisone-induced worsening of neuromuscular function in myasthenia gravis.
Topics: Action Potentials; Adult; Aged; Female; Humans; Muscle Contraction; Myasthenia Gravis; Neuromuscular | 1986 |
High-dose intravenous immunoglobulin in the management of myasthenia gravis.
Topics: Adult; Aged; Autoantibodies; Blood Proteins; Drug Therapy, Combination; Female; Humans; Infusions, P | 1986 |
[Eaton-Lambert syndrome. Long-term treatment with corticoids].
Topics: Adult; Female; Humans; Myasthenia Gravis; Prednisone; Time Factors | 1986 |
Myasthenia gravis in young.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Male; Myasthenia Gravis; Neostigmine; Prednison | 1986 |
[Treatment of myasthenia gravis by immunosuppressive non-steroidal drugs].
Topics: Adolescent; Adult; Aged; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; | 1986 |
Thymectomy in the treatment of myasthenia gravis.
Topics: Adolescent; Adult; Child; Child, Preschool; Combined Modality Therapy; Female; Humans; Male; Middle | 1985 |
Multiple dermatofibromas in a patient with myasthenia gravis treated with prednisone and cyclophosphamide.
Topics: Cyclophosphamide; Drug Therapy, Combination; Fibroma; Humans; Leg; Male; Middle Aged; Myasthenia Gra | 1986 |
Weakness and 'tiredness': when to suspect myasthenia gravis.
Topics: Aged; Antibodies; Diagnosis, Differential; Edrophonium; Electromyography; Fatigue; Female; Humans; M | 1985 |
[Ocular myasthenia].
Topics: Azathioprine; Blepharoptosis; Cholinesterase Inhibitors; Cortisone; Cyclophosphamide; Electromyograp | 1985 |
Immunosuppression with corticosteroids and thymectomy in myasthenia gravis: an evaluation of immediate and short term results in 20 patients.
Topics: Adolescent; Adult; Child; Cholinesterase Inhibitors; Drug Therapy, Combination; Female; Humans; Male | 1985 |
Short and long-term clinical effects of plasma-exchange in 33 cases of myasthenia gravis.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Cholinesterase Inhibitors; Female; Humans; Male; Middl | 1985 |
Treatment of myasthenic crisis in late life.
Topics: Adult; Aged; Cholinesterase Inhibitors; Combined Modality Therapy; Edrophonium; Female; Humans; Male | 1985 |
Glucocorticoid receptors of mononuclear leukocytes from myasthenia gravis patients.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Female; Humans; Lymphocytes; Male; Middle Aged; | 1985 |
Natural killer cell activity in multiple sclerosis and myasthenia gravis.
Topics: Adult; Female; Humans; In Vitro Techniques; Killer Cells, Natural; Male; Multiple Sclerosis; Myasthe | 1985 |
Alternate-dy prednisone in a patient with myasthenia gravis.
Topics: Administration, Oral; Adrenocorticotropic Hormone; Adult; Humans; Male; Myasthenia Gravis; Potassium | 1970 |
Continuous treatment of myasthenia gravis with prednisone.
Topics: Aged; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Myasthenia Gravis; Prednisone; P | 1971 |
Myasthenia gravis: a new hypothesis of the pathogenesis and a new form of treatment.
Topics: Adult; Axonal Transport; Axons; Child; Electromyography; Female; Humans; Male; Middle Aged; Motor Ne | 1971 |
Treatment of myasthenia gravis with prednisone.
Topics: Adult; Eye Manifestations; Female; Humans; Male; Middle Aged; Muscles; Myasthenia Gravis; Prednisone | 1972 |
Management of myasthenia gravis.
Topics: Adrenocorticotropic Hormone; Cholinesterase Inhibitors; Humans; Immunosuppressive Agents; Myasthenia | 1972 |
Adrenergic blockade in hypertension.
Topics: Autoimmune Diseases; Azathioprine; Dyspnea; Female; Hepatitis; Humans; Middle Aged; Myasthenia Gravi | 1972 |
Synergistic immunosuppressive action of antithymocyte antisera and thymectomy in the human.
Topics: Adolescent; Adult; Aged; Animals; Antibody Formation; Antilymphocyte Serum; Azathioprine; Blood Sedi | 1972 |
Thymoma, myasthenia gravis, erythroblastopenic anemia and systemic lupus erythematosus in one patient.
Topics: Ambenonium Chloride; Anemia, Aplastic; Autoimmune Diseases; Bone Marrow; Bone Marrow Cells; Bronchop | 1973 |
Myasthenia gravis and multiple sclerosis: an unusual combination of diseases.
Topics: Adult; Brain; Demyelinating Diseases; Diplopia; Edrophonium; Electroencephalography; Female; gamma-G | 1974 |
Studies in bullous diseases. Immunofluorescent serologic tests.
Topics: Adrenocorticotropic Hormone; Adult; Antibodies, Antinuclear; Autoantibodies; Basement Membrane; Blis | 1968 |
Myasthenia gravis, ulcerative colitis and lichen planus.
Topics: Adrenocorticotropic Hormone; Adult; Colitis, Ulcerative; Humans; Lichen Planus; Male; Myasthenia Gra | 1971 |
Myasthenia gravis and myasthenic syndromes treated with prednisone.
Topics: Adrenocorticotropic Hormone; Age Factors; Aged; Female; Humans; Male; Middle Aged; Myasthenia Gravis | 1971 |
Benefit from alternate-day prednisone in myasthenia gravis.
Topics: Action Potentials; Administration, Oral; Adult; Aged; Female; Humans; Male; Middle Aged; Muscles; My | 1972 |
[Principles and limits of ACTH-cortisone therapy in neurology].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Cortisone; Dexamethasone; Epilepsy; Facial Par | 1969 |
Corticosteroids in management of severe, generalized myasthenia gravis. Effectiveness and comparison with corticotropin therapy.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Evaluation Studies as Topic; Female; Humans; Male; Methylp | 1972 |
Optic neuropathy of Graves disease, hyperthyroidism, and ocular myasthenia gravis.
Topics: Adult; Eye Diseases; Graves Disease; Humans; Hyperthyroidism; Male; Myasthenia Gravis; Optic Nerve; | 1973 |
Prolonged respirator support for the treatment of intractable myasthenia gravis.
Topics: Adrenocorticotropic Hormone; Antilymphocyte Serum; Drug Therapy, Combination; Enteral Nutrition; Fem | 1974 |
Adverse interaction between steroid hormones and anticholinesterase drugs.
Topics: Action Potentials; Animals; Anura; Cholinesterase Inhibitors; Dexamethasone; Drug Interactions; Edro | 1974 |
The diagnosis and management of myasthenia gravis.
Topics: Adrenocorticotropic Hormone; Edrophonium; Electric Stimulation; Evoked Potentials; Fingers; Humans; | 1974 |
[Immuno suppressive drugs in the treatment of myasthenia (author's transl)].
Topics: Adrenocorticotropic Hormone; Autoimmune Diseases; Humans; Immunosuppressive Agents; Myasthenia Gravi | 1974 |
Long-term treatment of myasthenia gravis with alternate-day prednisone. Report on 15 patients.
Topics: Acetylcholine; Acetylcholinesterase; Action Potentials; Administration, Oral; Adolescent; Adult; Age | 1974 |
Is myasthenia gravis an autoimmune disease?
Topics: Adult; Autoimmune Diseases; Cholinesterase Inhibitors; Female; Humans; Myasthenia Gravis; Prednisone | 1973 |
Ophthalmoplegia in dermatomyositis.
Topics: Aspartate Aminotransferases; Creatine Kinase; Dermatomyositis; Diagnosis, Differential; Edrophonium; | 1973 |
Adverse interaction between corticosteroid hormones and anticholinesterase drugs.
Topics: Animals; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Glucocortic | 1973 |
Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment.
Topics: Adult; Aged; Cholinesterase Inhibitors; Evaluation Studies as Topic; Female; Humans; Male; Middle Ag | 1974 |
Letter: Prednisone schedule for myasthenia gravis.
Topics: Adult; Aged; Female; Humans; Male; Myasthenia Gravis; Prednisone; Time Factors | 1974 |
Ulcerative colitis, myasthenia gravis, atypical lichen planus, alopecia areata, vitiligo.
Topics: Adult; Alopecia Areata; Autoantibodies; Biopsy; Chlordiazepoxide; Colitis, Ulcerative; Humans; Immun | 1974 |
Oral corticosteroids in the treatment of ocular myasthenia gravis.
Topics: Administration, Oral; Adult; Aged; Blepharoptosis; Child, Preschool; Cholinesterase Inhibitors; Edro | 1974 |
Cell-mediated immunity in polymyositis. Creatine phosphokinase release from muscle cultures.
Topics: Adolescent; Adult; Aged; Autoimmune Diseases; Azathioprine; Child; Creatine Kinase; Culture Techniqu | 1974 |
Immunosurveillance and cancer: epidemiological evidence.
Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Chediak-Higashi Syndrome; Child; Child, Preschoo | 1970 |
[Coexistence of pemphigus erythematosus and myasthenia gravis].
Topics: Adult; Antibodies, Antinuclear; Dexamethasone; Female; Fluorescent Antibody Technique; Humans; Myast | 1970 |
Pathogenesis of myasthenia gravis.
Topics: Biopsy; Child; Female; Humans; Hyperthyroidism; Lymph Nodes; Myasthenia Gravis; Prednisone; Sarcoido | 1971 |
[Myasthenia gravis. Some clinical aspects].
Topics: Adolescent; Adult; Aged; Autopsy; Child; Diagnosis, Differential; Electromyography; Eye Manifestatio | 1971 |
[Anemia caused by erythroblastopenia in adult age].
Topics: Aged; Analgesics; Anemia, Aplastic; Azathioprine; Blood Transfusion; Female; Heart Failure; Hepatiti | 1970 |
The syndrome of myasthenia and polymyositis with comments on therapy.
Topics: Adolescent; Adult; Aged; Autoimmune Diseases; Diagnosis, Differential; Female; Humans; Male; Middle | 1971 |
[Therapy of myasthenia gravis pseudoparalytica].
Topics: Antineoplastic Agents; Child; Female; Humans; Infant; Methotrexate; Myasthenia Gravis; Paralysis; Pr | 1970 |
Pathogenesis of myasthenia gravis.
Topics: Animals; Autoimmune Diseases; Freund's Adjuvant; Humans; Hyperthyroidism; Myasthenia Gravis; Myocard | 1971 |
[Polymyositis and myasthenia. Chronic pure polymyositis of myasthenic and pseudomyasthenic form].
Topics: Adult; Autoimmune Diseases; Biopsy; Chronic Disease; Diagnosis, Differential; Electromyography; Fema | 1967 |
Myasthenia gravis syndrome in sarcoidosis and hyperthyroidism: a case report.
Topics: Adult; Humans; Hyperthyroidism; Male; Mediastinal Diseases; Myasthenia Gravis; Prednisone; Propylthi | 1966 |